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There is plenty of evidence from epidemiology studies  
supporting a link between certain components in the human  
diet and cancer incidence. It is estimated that 3-4 million  
annual cases of cancer could be prevented worldwide just by  
changing dietary habits. In parts of the world where  
vegetables and fruits constitute a large part of the diet,  
certain cancer incidences are markedly lower compared to  
Western countries. In particular, consumption of cruciferous  
vegetables is negatively associated with occurrence of  
certain cancers. One of the compounds from crucifers that is  
implicated in chemoprevention, is indole-3-carbinol(I3C),  
documented to inhibit tumor formation in several tissues in  
Redacted for Privacyrodents, including the mammary tissue. I3C and is currently  
being evaluated in several clinical trials as a  
chemopreventive agent against breast cancer in humans. There  
are, however, some legitimate concerns regarding the use of  
Pure I3C since, depending upon conditions of administration,  
I3C can act as a promoter of hepatocarcinogenesis. Evidence  
is presented here that dietary I3C can promote and/or  
enhance liver tumor formation in rainbow trout (supporting  
earlier reports in literature) and the C57BL/6J mouse  
(enhancement in short-term pre-initiation exposure through  
lactational transfer, inhibition in a long-term post- 
initiation feeding study). I3C is also reported to promote  
in the rat liver model. A major concern associated with  
dietary I3C supplementation relates to its estrogenic  
effects as seen in trout and also its ability to induce  
certain cytochrome P-450s involved in procarcinogen  
activation. Biological effects of I3C are attributed to its  
acid condensation products. It was observed in this study that  
I3C acts through different mechanisms, including the Ah  
receptor-mediated and estrogenic pathways. Understanding of  
the role of I3C derivatives in beneficial and/or hazardous  
effects resulting from dietary exposure will be crucial in  
evaluating the promise of I3C as a chemoprevention agent.  
Questions pertaining to the risk/benefit of the use of dietary  
I3C supplementation for preventing estrogen-related diseases,  without increasing the risk of promotion of  
hepatocarcinogenesis in humans, may depend on whether the  
mechanism(s) of action of I3C derivatives in humans is more  
like the adult mouse or the neonatal mouse, rat and trout.  ©Copyright by Aram Oganesian  
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Chapter 1  
INTRODUCTION  
Almost on a daily basis, the news media reports on the  
presence of one chemical or another that is present in the  
human diet and is claimed to be carcinogenic, or  
anticarcinogenic. The public is being bombarded with reports  
that raise both fear and hope. Ever more popular have become  
numerous dietary supplements mainly originating from plants,  
and the health food industry is growing faster than ever.  
It has been found from epidemiology studies that  
components of the human diet have some associations with the  
incidence of certain cancers (1, 2). It is believed that 15-
65 % of all cancer occurrences are diet-related (1). For  
instance, a higher incidence of stomach cancer has been  
linked to the consumption of salty foods, or lack of intake  
of fruits and vegetables (3), and a higher occurrence of  2 
colorectal cancer is associated with high intake of fat in  
the diet (4). Epidemiology studies also demonstrate that, in  
parts of the world where fruits and vegetables are a large  
part of the diet, the incidence of certain cancers in the  
population is lower (5,  6). The American Cancer Society and  
other health authorities have issued a series of dietary  
recommendations designed to lower the incidence of cancers  
believed to be diet-related. It is estimated that 3-4  
million cases of cancers worldwide (350-400 thousand in the  
US) could be prevented annually just by changing dietary  
habits in the population (6). Although advances in the  
medical field have significantly improved the rate of cure  
for some types of cancer, the five year survival rate of  
cancer patients in the United States was only 51 % in 1992  
(7). Not surprisingly, preventative approaches to  
controlling cancer appear to offer a healthy alternative in  
decreasing overall mortality in humans who are at high risk  
for cancer. The Chemoprevention Branch of the Prevention  
Program, Division of Cancer Prevention and Control, National  
Cancer Institute, has, as part of their responsibilities,  
the task to identify and characterize potential candidate  
compounds for chemoprevention (8). Among several naturally  
occurring compounds, indole-3-carbinoll (I3C2) has received  
serious consideration.  
1 Synonyms include 3-indolylcarbinol, indole-3-carbinole, indol- 3- ylcarbinol, indol- 3- ylmethanol, indole-
3-methanol, 3-indolemethanol and 3-hydroxymethylindole. Indole-3-carbinol remains widely used and 3 
I3C is a plant secondary metabolite, found in naturally  
occurring form as a breakdown product of glucobrassicin, the  
most common member of a class of compounds known as  
glucosinolates (9). High levels of glucosinolates have been  
identified in the family of Cruciferae. Representative  
plants from this family include broccoli, cabbage,  
cauliflower, Brussels sprouts, etc. Glucobrassicin undergoes  
enzymatic hydrolysis upon maceration of plant tissue at  
neutral pH, yielding glucose, sulfate, thiocyanate ion and  
I3C (Fig. 1.1). In the conditions of lower pH, another  
pathway yields indole-3-acetonitrile, hydrogen sulfide and  
elemental sulfur. Both pathways are catalyzed by the plant  
enzyme myrosinase (thioglucoside glucohydrolase, E.C.  
3.2.3.1). Once formed, I3C may undergo condensation into  
3,3'-diindolylmethane (133') or, into ascorbigen in the  
presence of L-ascorbic acid, found at relatively high levels  
in cruciferous plants. For experimental purposes, I3C can be  
commercially obtained from different sources (in this study,  
from Aldrich Chemical Company, Inc. (Milwaukee, WI)). For  
the purposes of this thesis, discussion will be limited to  
I3C and its acid condensation products. For an overview of  
more details in chemical and biological properties of indole  
referred to in the literature and, for consistency, will be used here. 
2 Abbreviations: Ah, aryl hydrocarbon; 13C, indole-3-carbinol; 133', 3,3 '-diindolylmethane; LT, linear 
trimer, [2-(indo1-3-ylmethyl)-indol-3-yl]indol-3-ylmethane); CT, cyclic trimer (5,6,11,12,17,18-
hexahydrocyclonona[1,2-6:4,5-b':7,8-bltriindole); ICZ, indolo[3,2- b]carbazole; ANF, a-naphthoflavone; 
BNF, p-naphthoflavone; HCB, hexachlorobiphenyl; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. 4 
glucosinolates, the reader is referred to an excellent  
review by McDannell et a/.(9).  
Beneficial Effects of I3C  the Chemoprevention Promise.  
As early as 1975, Wattenberg and colleagues (10)  
demonstrated that when administered orally, I3C could  
induced aryl hydrocarbon hydroxylase (AHH) activity in  
hepatic and intestinal tissue. This finding resulted in the  
beginning of the interest in I3C as a possible  
chemopreventive agent. Later, the promise of I3C was  
substantiated significantly when it was shown to inhibit  
mammary tumor formation induced by 7,12-
dimethylbenz[a]anthracene (DMBA) in female Sprague-Dawley  
rats and neoplasia of the forestomach induced by  
benzo[a]pyrene (BaP) in female ICR/Ha mice (11). I3C  
possesses characteristics that are very desirable for a  
potential chemopreventive agent. For example, I3C exhibits  
very low acute toxicity (12-14) and does not appear to have  
teratogenic properties (12). The anticarcinogenic activity  
of dietary I3C in the form of inhibition of tumors and/or  
DNA-adduct formation has been observed against several  
classes of environmentally relevant carcinogens, including  
nitrosamines (15-23), PAHs (11, 24-27), the mycotoxin,  
aflatoxin B1  (AFB1)  (28-33), and the nitroazarene, 4-
nitroquinoline 1-oxide (34). It was the demonstration of  5 
protection against estrogen-related tumors (35-37) that  
suggested the use of I3C as a chemopreventive agent against  
human breast cancer. In fact, short-term studies with I3C in  
humans indicated that protection may occur against estrogen- 
responsive breast cancer development (38, 39). Such capacity  
to protect against many different carcinogens is a highly  
desirable feature in a chemopreventive compound, given the  
diverse etiology of human cancer (1,2). The apparent lack of  
specificity in protection of various target organs  
constitutes another desirable characteristic of I3C. Various  
reports indicate I3C-mediated chemoprotection in the liver  
(16, 23, 29, 30, 40) forestomach (11) or stomach (27), lung  
(16,  17, 25), mammary tissue (11, 24, 35), larynx (36),  
tongue (34), nasal mucosa (17), swim bladder (27) and  
endometrium (37). Furthermore, chemoprotection from I3C does  
not seem to be species-specific as it was observed in mice  
(17, 23, 36, 35), rats (18 34, 22, 33), and trout (15, 27-
30, 40). Evidence from mechanistic studies in other species  
(hamsters, chick embryo and monkey hepatocytes) suggest that  
similar outcome could occur in them as well (41, 26, 42).  
There are also encouraging preliminary results in humans  
(38,39).  6 
Concerns Regarding Dietary I3C Exposure  
The enthusiasm associated with the potential of I3C to  
act as a chemopreventive agent against cancer might be a  
little premature, as several studies indicate an absence of  
protection, or even significant adverse effects, with  
dietary I3C treatment. For example, no protection was  
observed with a 12 week exposure to 0.5% dietary I3C,  
following treatment with N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), on the incidence of pepsinogen 1-
decreased pyloric glands (a suggested preneoplastic marker  
of stomach tumorigenesis)  (43). Pretreatment with dietary  
I3C in rats initiated with the tobacco-specific nitrosamine  
4-(methylnitroamino)-1-(3-pyridy1)-1-butanone (NNK) reduced  
levels of 7-methylguanine adducts in lung and nasal mucosa  
DNA, however, it significantly elevated levels of DNA  
adducts in the liver (16). There is some evidence that, when  
administered in diet along with nitrites, I3C may have an  
indirect role in the process of initiation by acting as a  
mutagen (44,  45) .  
Despite having wide-range chemopreventive properties  
against tumorigenesis, I3C has also been implicated in  
enhancement and/or promotion of carcinogenesis in several  
animal models. In mouse epidermis, the 12-0-tetradecanoyl  
phorbol-13-acetate induction of ornithine decarboxylase  
activity (a marker for tumor promoting activity) was shown  7 
to be elevated by I3C (46). Dietary I3C enhanced tumor  
incidence in rats when given before, during, and after  
treatment with the colon specific carcinogen  
dimethylhydrazine (DMH)  (47). Fecal extracts from rats given  
DMH and I3C were mutagenic in the Ames test, but  
mutagenicity was not related to metabolites of DMH (48). The  
importance of the timing of dietary I3C exposure in deciding  
tumor outcome was demonstrated in the trout tumor model.  
When given before and during administration of the  
carcinogens DMBA (27) or AFB1 (28), I3C reduced the numbers  
of tumors observed. However, when fed post-initiation, a  
significant, dose-dependent increase in the number of tumors  
was seen (27, 49). For AFB1, the ability of I3C to enhance  
or inhibit tumors was nearly equal over a range of doses  
(14). Promotion of hepatotumorigenesis was also observed in  
rats fed I3C after initiation (50).  
Several I3C acid condensation derivatives (Fig. 1.2)  
have been shown to mediate toxicity by a mechanism similar  
to that described for 2,3,7,8-tetrachlorodibenzo-p-dioxin  
(TCDD)  (51), a known toxic agent and tumor promoter. This is  
presumed to be due to an ability to bind to the Ah receptor.  
The most potent agonist among the I3C-related compounds is  
indolo[3,2-b]carbazole (ICZ)  (52, 53). ICZ possesses a  
binding affinity for the Ah receptor close to that of TCDD  
and other toxic (carcinogenic and teratogenic) Ah receptor  8 
ligands (54, 55). Like TCDD, ICZ has immunosuppressive,  
estrogenic and antiestrogenic activities (56). Several other  
I3C derivatives also bind to the Ah receptor (52, 53, 57,  
58).  
I3C administration has also been shown to result in  
toxicity in the form of depletion of glutathione in the  
liver, elevation of hepatic enzyme levels in plasma, and, at  
very high dietary levels, I3C also can be neurotoxic (59).  
Mechanisms of carcinogenesis modulation by 13C  
Elucidation of the mechanism(s) of action of potential  
chemopreventive agents is essential in evaluating the  
benefit of their administration. According to the  
classification system for chemopreventive compounds  
suggested by Wattenberg (60), I3C is classified as a  
blocking agent, meaning it protects against carcinogenesis  
by preventing the carcinogenic agents from reaching and/or  
reacting with critical target sites in the cell. Also, under  
certain conditions, I3C could act as a suppressive agent  
(22, 34). There are several mechanisms by which a blocking  
agent could inhibit the manifestation of cancer, including  
(i) induction of biotransformation enzymes responsible for  
detoxification pathway(s), (ii)inhibition or inactivation of  
cytochrome(s) P-450 (CYP) responsible for bioactivation of  
procarcinogens and (iii)physico-chemical interaction with  9 
carcinogens (i.e. nucleophilic trapping of electrophiles or  
formation of complex(s)). I3C and/or its acid condensation  
derivatives are implicated in all three of these mechanisms.  
Originally, protective effects seen after dietary I3C  
administration were thought to be due to the ability of I3C  
to induce CYP1A1-mediated AHH activity (10, 11). The ability  
of I3C to induce CYP has been extensively documented at the  
level of protein and associated catalytic activities (25,  
35, 37-39, 41, 42, 47, 53, 58, 59, 61-68) as well as  
enhanced gene transcription (69, 70). Most studies have  
focused on induction in the liver and intestinal tissue,  
however, induction has been reported in other organ sites  
including kidney (71), lung (41), and colon (69). The most  
commonly induced CYP isozyme is CYP1A1 (53,  58,  68,  69) .  
Cyplal is one of the battery of genes whose transcription is  
activated in the presence of Ah receptor agonists (72).  
Other P-450 isozymes reported to be induced by I3C and/or  
derivatives include CYP1A2 (42, 58,  62,  68, 69), CYP2B1 (25,  
42, 58,  68,  69) and CYP3A (62,  68) .  It is proposed that  
most, if not all, of the induction observed upon dietary I3C  
administration is due to condensation products rather than  
I3C itself (25, 53,  65, 73). ICZ has been suggested to be  
important in enzyme induction since, among 13C-related  
derivatives, it possesses the highest affinity for binding  
towards the Ah receptor (54, 55). However, in most studies  10 
it has been found in extremely low concentrations. Other I3C  
acid condensation derivatives, such as 133'  (a major  
derivative that could also be formed from I3C in aqueous  
solutions(74)), linear trimer (LT,  [2-(indo1-3-ylmethyl)-
indol-3-yl]indol-3-ylmethane), and cyclic trimer (CT,  
5,6,11,12,17,18-hexahydrocyclonona[1,2-b:4,5-b':7,8-
b"]triindole) also have P-450 inducing properties (42,  57,  
75). The total induction observed upon dietary I3C exposure  
is certainly the additive effect from all derivatives and  
thus the relative contribution of each would depend upon  
their concentration as well as the efficacy.  
Another, perhaps more important mechanism for  
protection, is the ability of I3C to inhibit the binding of  
carcinogens to DNA in the absence of detectable induction of  
AHH or other CYP activity in mice (19, 76) or trout(77, 78,  
110) .  
It is important to note that induction of hepatic  
CYP1A1 and CYP1A2, the most readily induced isoforms by  
dietary I3C, is implicated in bioactivation of a number of  
dietary carcinogens (79) including BaP (25) and AFB1 (32,  
111) .  
Besides phase I enzymes (enzymes introducing functional  
groups into the chemical structure of xenobiotics) described  
above, dietary I3C can also induce some phase II enzymes  
(enzymes responsible, for conjugating endogenous ligands with  11 
functional groups introduced in Phase I  (80)). Normally,  
phase II enzymes are involved in detoxifying pathways and  
are not carcinogen- or tissue-specific (60, 81). Thus,  
agents inducing only phase II enzymes are more desirable as  
chemoprevention candidates than those inducing both phase I  
and II enzymes. Among phase II enzymes, of particular  
interest are UDP-glucuronosyl transferases (UDPGT),  
glutathione-S-transferases (GST, conjugates glutathione with  
carcinogenic electrophiles), epoxide hydrolase (EH,  
conjugates water with reactive epoxides) and quinone  
reductase (prevents oxidative cycling and glutathione  
depletion by reducing quinones). I3C was shown to induce QR  
(13,  42,  59,  66,  82), UDPGT  (13, 26 59), EH (83), and GST  
(13,  59,  84-86).  Of these,  induction of GST subunit Yc2 is  
believed to provide protective effects against AFB1- induced  
carcinogenesis (84). The induction of other phase II enzymes  
by I3C is not consistent (77,  83,  63,  87) hence their role  
in I3C protection is not entirely clear.  
Dietary I3C inhibited flavin -containing monooxygenase  
form 1  (FMO) activity and expression in rat liver and  
intestine (88) and altered the ratio of FMO/CYP. FMOs are  
involved mainly in detoxifying xenobiotics and their  
inhibition by I3C is a reason for concern. The simultaneous  
induction of CYP and repression of FMO by animals fed I3C  
could have profound effects on the disposition and/or  12 
toxicity of xenobiotics which are substrates for both  
monooxygenases.  
Other proteins are also reported to be affected in  
response to dietary I3C. Among them, cytosolic UDP-glucose  
dehydrogenase (required for formation of UDP-glucuronic  
acid, a cofactor of UDPGT), and microsomal NADPH-cytochrome  
c-reductase and cytochrome b5, all of which were elevated  
(83). Another enzyme elevated upon I3C administration  
(gavage) was glutathione reductase (59) which promotes the  
availability of glutathione. Conversely, reduced activities  
were observed for superoxide dismutase and glutathione  
peroxidase; both enzymes are involved in protection against  
oxidative stress.  
Another mechanism of action of I3C derivatives (133'  
and CT) in anticarcinogenesis, not related to enzyme  
induction, is the ability to inhibit mutagenesis which was  
demonstrated with carcinogen AFB1 in vitro (89).  
Numerous studies have investigated the possible  
antioxidant and electrophile scavenging properties of I3C  
(19-21, 76, 90,  91) and it appears that most of these  
properties are due to ascorbigen which is formed from I3C  
and L-ascorbic acid (9,  92). The relative role of I3C as an  
antioxidant in anticarcinogenesis remains to be evaluated   .  
In protecting against carcinogenesis in the mammary  
tissue, the main mechanism is proposed to be the  13 
antiestrogenicity of I3C and/or derivatives which is  
manifested as an alteration of estrogen metabolism (35, 93-
97). However, as is presented in chapter 3, dietary I3C may  
also have estrogenic activities. Estrogens are reported to  
promote chemically-induced hepatocarcinogenesis in trout (98)  
and rats (99-104). In humans, certain estrogens (oral  
contraceptives) are documented to promote hepatic adenomas and  
carcinomas (105, 106).  
Other possible mechanisms for I3C modulation of  
carcinogenesis are proposed in the scientific literature. One  
of them is the reported ability of I3C to increase the  
activity of the DNA repair enzyme 06-mGua-DNA-transmethylase  
(16). Another possibility involves inhibition of cytosolic  
steroid binding activity by I3C acid derivatives (86), which  
might offer protection by interfering with GST-mediated  
intracellular transport of steroids and carcinogens.  
Modulation (reversal) of the multidrug resistance (107) is  
another possible mechanism of action. 133' is capable of  
inducing apoptosis in human cancer cells (108), suggesting one  
more possible mechanism for protection.  
Other Biological Effects of Dietary I3C  
In addition to tumor modulatory properties, dietary I3C  
intake is reported to have lowered serum LDL (low density  
lipoprotein) and VLDL (very low density lipoprotein) levels  14 
(109) which was attributed to the inhibition of acyl-
CoA:cholesterol acyltransferase.  
Summary  
It appears that dietary I3C may act both as a protective  
and promoting agent in carcinogenesis in various animal models  
depending on several factors including the timing of  
administration. When given subsequent to initiation, I3C may  
act as a promoter whereas, in most cases, pretreatment and co-
treatment with the carcinogen resulted in protection. As will  
be shown in chapter 6, pretreatment with I3C prior to  
initiation can also enhance tumor outcome. The relative role  
of the many possible mechanisms involved, however, is not yet  
completely understood.  
Inhibition of CYP bioactivation, induction of CYP  
detoxification, and induction of phase II enzymes are some of  
the mechanisms responsible for chemoprotective effects of  
dietary I3C. Several other possible mechanisms may also play a  
role. Among them, electrophile and/or radical scavenging,  
inhibition of intracellular steroid transport and binding,  
induction of apoptosis, and antiestrogenicity (by mechanisms  
other than the alteration of estrogen metabolism (i.e.  
estrogen receptor antagonism)).  
Tumor enhancing effects of dietary I3C might be  
explained by two main candidate mechanisms, bioactivation of  15 
carcinogens through the induction of mainly phase I enzymes,  
and the potential of some I3C derivatives to alter cellular  
proliferation by acting as estrogens. Evidence is presented in  
this work that both of the above mechanisms could be active in  
explaining the observed promotion of hepatocarcinogenesis in  
trout and the enhancement in the mouse.  
Especially important might be the potential of I3C  
and/or derivatives in acting as estrogens in humans. Concerns  
are raised pertaining to the possible risk(s) for promoting  
hepatic tumors in humans by long-term I3C supplementation, as  
it is known that certain estrogens (oral contraceptives)  
promote hepatic tumors in humans.  Glucobrassicin  N 0S03 
glucose 
+S 
pH 3-7
Myrosinase 
H2O 
OH 
+ SCN-
H  
Indole-3-carbinol Indole-3-acetonitrile 
N  
H H 
3,3'-diindolylmethane 
CH2SCN 
IM-Isothiocyanate 
OH 
C) 
OH  OH 
N  
Ascorbigen 
Figure 1.1. Formation of I3C from enzymatic hydrolysis of glucobrassicin in cruciferous  
vegetables.   5; Acid Condensation Products of 13C  
133' 
OH  
SEVERAL OTHER 
OLIGOMERS I3C 
If 
ICZ LT 
(adopted from Dr. D. Strasser) 
CT 
Figure 1.2. Formation of acid condensation products from 13C. HI-IM, 133', dimers; LT  
linear trimer; CT, cyclic trimer, CT, cyclic trimer; ICZ, indolo[3,2-
b]carbazole; I3C, indole-3-carbinol.  18 
REFERENCES  
1.	  R. Doll and R. Peto: The causes of cancer: Quantitative  
estimates of avoidable risks of cancer in the United  
States today. J. Natl. Cancer Inst. 66, 1193-1308  
(1981) .  
2.	  R. Doll: The lessons of life: keynote address to the  
nutrition and cancer conference. Cancer Res.  (suppl.)  
52, 2024s-2029s (1992).  
3.	  D. Forman: The aetiology of gastric cancer: 10th  
international meeting on n-nitroso compounds,  
mycotoxins and tobacco smoke: relevance to human  
cancer. Lyon, France: International Agency for Research  
on Cancer, 1989.  
4.	  R.L. Prentice and L. Sheppard: Dietary fat and cancer:  
consistency of the epidemiologic data and disease  
prevention that may follow from a practical reduction  
in fat calories. Cancer Causes Control 1, 81-97 (1990).  
5.	  G. Block, B. Patterson and A. Subar: Fruit, vegetables  
and cancer prevention: A review of the epidemiological  
evidence. Nutr. Cancer 18, 1-29 (1992).  
6.	  National Research Council. Carcinogens and  
Anticarcinogens in the Human Diet: A Comparison of  
Naturally Occurring and Synthetic Substances. National  
Academy Press, Washington D.C. 1996.  
7.	  Cancer facts and Figures  1992. American Cancer  
Society, pp.1-3 (1992).  
8.	  C.W. Boone, G.J. Kelloff and W.E. Malone:  
Identification of candidate cancer chemopreventive  
agents and their evaluation in animal models and human  
clinical trials: a review. Cancer Res. 50, 2-9 (1990).  
9.	  R. McDannell, A.E.M. Mclean, A.B. Hanley, R.K. Heaney,  
and G.R. Fenwick: Chemical and biological properties of  
indole glucosinolates (glucobrassicins). Fd. Chem.  
Toxicol. 26, 59-70 (1988).  
10.	  W.D. Loub, L.W. Wattenberg and D.W. David: Aryl  
hydrocarbon hydroxylase induction in rat tissues by  
naturally occurring indoles of cruciferous plants. J.  
Natl. Cancer Inst. 54, 985-988 (1975).  19 
11.	  L.W. Wattenberg and W.D. Loub: Inhibition of polycyclic  
aromatic hydrocarbon-induced neoplasia by naturally  
occurring indoles. Cancer Res. 38, 1410-1413 (1978).  
12.	  K. Nishie and M.E. Daxenbichler: Toxicology of  
glucosinolates, related compounds (nitriles, R-goitrin,  
isothiocyanates) and vitamin U found in cruciferae. Fd.  
Cosmet. Toxicol. 18, 159-172 (1980).  
13.	  H.G. Shertzer and M. Sainsbury: Intrinsic acute  
toxicity and hepatic enzyme inducing properties of the  
chemoprotectants indole-3-carbinol and 5,10-
dihydroindeno[1,2-b]indole in mice. Fd. Chem. Toxicol.  
29, 237-242 (1991).  
14.	  R.H. Dashwood, A.T. Fong, D.E. Williams, J.D.  
Hendricks, and G.S. Bailey: Promotion of aflatoxin B1  
carcinogenesis by the natural tumor modulator indole-3-
carbinol: influence of dose, duration and intermittent  
exposure on indole-3-carbinol promotional potency.  
Cancer Res. 51, 2362-2365 (1991).  
15.	  A.T. Fong, J.D. Hendricks, R.H. Dashwood, S. Van  
Winkle, B.C. Lee, and G.S. Bailey: Modulation of  
diethylnitrosamine-induced hepatocarcinogenesis and 06-
ethylguanine formation in rainbow trout by indole-3-
carbinol, B-naphthoflavone, and aroclor 1254. Toxicol.  
Appl. Pharmacol. 9, 93-100 (1988).  
16.	  M.A. Morse, C. Wang, S.G. Amin, S.S. Hecht and F.  
Chung: Effects of dietary sinigrin or indole-3-carbinol  
on 06-methylguanine-DNA-transmethylase activity and 4-
(methylnitrosamino)-1-(3-pyridy1)-1-butanone-induced  
DNA methylation and tumorigenicity in F344 rats.  
Carcinogenesis 9, 1891-1895 (1988).  
17.	  M.A. Morse, S.D. LaGreca, S.G. Amin, and F.L. Chung:  
Effects of indole-3-carbinol on lung tumorigenesis and  
DNA methylation induced by 4-(methylnitrosamino)-1-(3-
pyridy1)-1-butanone (NNK) and on the metabolism and  
disposition of NNK in A/J mice. Cancer Res., 50, 2613-
2617 (1990).  
18.	  T. Tanaka, Y. Mory, Y. Morishita, A. Hara, T. Ohno, T.  
Kojima, and H. Mori.: Inhibitory effect of sinigrin and  
indole-3-carbinol on diethylnitrosamine-induced  
hepatocarcinogenesis in male ACl/N rats. Carcinogenesis,  
11,1403-1406 (1990).  20 
19.	  H.G. Shertzer: Indole-3-carbinol protects against  
covalent binding of benzo(a)pyrene and N-
nitrosodimethylamine metabolites to mouse liver  
macromolecules. Chem.-Biol. Interact. 48, 81-90 (1984).  
20.	  H.G. Shertzer, M.W. Tabor and M.L. Berger: Protection  
from N-nitrosodimethylamine-mediated liver damage by  
indole-3-carbinol. Exp. Molec. Pathol. 47, 211-218  
(1987) .  
21.	  A.G. Shertzer and M.W. Tabor: Nucleophilic index value:  
implication in the protection by indole-3-carbinol from  
N-nitrosodimethylamine cyto- and genotoxicity in mouse  
liver. J. Appl. Toxicol. 8, 105-110 (1988).  
22.	  J.J. Jang, K.J. Cho, Y.S. Lee, and J.H. Bae: Modifying  
responses of allyl sulfide, indole-3-carbinol and  
germanium in a rat multi-organ carcinogenesis model.  
Carcinogenesis 12, 691-695 (1991).  
23.	  A. Oganesian, J.D. Hendricks, and D.E. Williams: Long  
term dietary indole-3-carbinol inhibits  
diethylnitrosamine-initiated hepatocarcinogenesis in the  
infant mouse model. Cancer Lett., 118, 87-94 (1997).  
24.	  L.W. Wattenberg: Inhibition of carcinogenesis by minor  
anutrient constituents of the diet. Proc. Nutr. Soc. 49,  
173-183 (1990)  .  
25.	  J.-Y. Park and L.F. Bjeldanes: Organ-selective induction  
of cytochrome P-450-dependent activities by indole-3-
carbinol-derived products: influence on covalent binding  
of benzo[a]pyrene to hepatic and pulmonary DNA in the  
rat. Chem.-Biol. Interact. 83, 235-247 (1992).  
26.	  W.M.F. Jongen, R.J. Topp, P.J. van Bladeren, J. Lapre,  
K.J.H. Wienk, and R.Leenen: Modulating effects of  
indoles on benzo[a]pyrene-induced sister chromatid  
exchanges and the balance between drug metabolizing  
enzymes. Toxicol. In Vitro 3, 207-213 (1989).  
27.	  J.D. Hendricks, P.M. Loveland, D.N. Arbogast, R.-C.  
Cheng, and G.S. Bailey: Inhibition and promotion of  
7,12-dimethylbenz[a]anthracene (DMBA) carcinogenesis in  
rainbow trout by indole-3-carbinol (I3C). Proc. Am.  
Assoc. Cancer Res. 35, 3745 (1994).  
28.	  J.E. Nixon, J.D. Hendricks, N.E. Pawlowski, C. Pereira,  
R.O. Sinnhuber, and G.S. Bailey: Inhibition of aflatoxin  21 
B1 carcinogenesis in rainbow trout by flavone and indole  
compounds. Carcinogenesis 5, 615-619 (1984).  
29.	  R.H. Dashwood, D.N. Arbogast, A.T. Fong, J.D. Hendricks,  
and G.S. Bailey: Mechanisms of anticarcinogenesis by  
indole-3-carbinol: detailed in vivo DNA binding dose- 
response studies after dietary administration with  
aflatoxin Bl. Carcinogenesis 9, 427-432 (1988).  
30.	  R.H. Dashwood, D.N. Arbogast, A.T. Fong, C. Pereira,  
J.D. Hendricks, and G.S. Bailey: Quantitative inter-
relationships between aflatoxin Bi carcinogen dose,  
indole-3-carbinol anticarcinogen dose, target organ  
adduction and final tumor response. Carcinogenesis 10,  
175-181 (1989) .  
31.	  D.E. Goeger, D.W. Shelton, J.D. Hendricks, and G.S.  
Bailey: Mechanisms of anti-carcinogenesis by indole-3-
carbinol: effect on the distribution and metabolism of  
aflatoxin Bl in rainbow trout Carcinogenesis 7, 2025-
2031 (1986)  .  
32.	  A.D. Salbe and L.F. Bjeldanes: Effect of diet and route  
of administration on the DNA binding of aflatoxin B1 in  
the rat. Carcinogenesis 10, 629-634 (1989).  
33.	  D.M. Stresser, D.E. Williams, D.A. Griffin, and G.S.  
Bailey, G.S.: Mechanisms of tumor modulation by indole-
3-carbinol. Disposition and excretion in male Fischer  
344 rats. Drug Metabol. Dispos., 23, 965-975 (1995).  
34.	  T. Tanaka, T. Kojima, Y. Morishita, and H. Mori:  
Inhibitory effects of the natural products indole-3-
carbinol and sinigrin during initiation and promotion  
phases of 4-nitroquinoline-l-oxide-induced rat tongue  
carcinogenesis. Jpn. J. Cancer Res., 83, 835-842 (1992).  
35.	  H.L. Bradlow, J. Michnovicz, N.T. Telang, and M.P.  
Osborne: Effects of indole-3-carbinol on estradiol  
metabolism and spontaneous mammary tumors in mice.  
Carcinogenesis, 12, 1571-1574 (1991).  
36.	  L.A. Newfield, A. Goldsmith, H.L. Bradlow and K.  
Auburn: Estrogen metabolism and human papillomavirus-
induced tumors of the larynx: chemoprophylaxis with  
indole-3-carbinol. Anticancer Res. 13, 337-342 (1993)  
37.	  T. Kojima, T. Tanaka, and H. Mori: Chemoprevention of  
spontaneous endometrial cancer in female Donryu rats by  22 
dietary indole-3-carbinol. Cancer Res. 54, 1446-1449  
(1994) .  
38.	  J.J. Michnovicz and H.L. Bradlow: Induction of  
estradiol metabolism by dietary indole-3-carbinol in  
humans. J. Natl. Cancer Inst. 82, 947-949 (1990).  
39.	  J.J. Michnovicz and H.L. Bradlow: Altered estrogen  
metabolism in humans following consumption of indole-3-
carbinol. Nutr. Cancer 16, 59-66 (1991)  
40.	  G.S. Bailey,D.E. Williams, and J.D. Hendricks: Fish  
models for environmental carcinogenesis: the rainbow  
trout. Environ. Health Perspect. 104 (suppl. 1), 5-21  
(1996) .  
41.	  P.H.M. Hoet and B. Nemery: Effects of environmental  
chemicals on drug biotransformation in the lung. ISSX  
Proceedings 3, 145 (1993).  
42.	  H.M. Wortelboer, C.A. de Kruif, A.A.J. van Iersel, H.E.  
Falke, J. Noordhoek, and B.J. Blaauboer: Acid reaction  
products of indole-3-carbinol and their effects on  
cytochrome P450 and phase II enzymes in rat and monkey  
hepatocytes. Biochem. Pharmacol. 43, 1439-1447 (1992).  
43.	  J.J. Jang, K.J. Cho, N.H. Myong, S.H. Kim, and S.J. Lee:  
Modifying effects of capsaicin, allyl sulfide, indole-3-
carbinol and germanium on the induction of pepsinogen 1  
altered pyloric glands in rats initiated with N-methyl-
N'-nitro-N-nitrosoguanidine. Environ. Mutat.  
Carcinogen. 9, 47-55 (1989)  
44.	  C. Sasagawa and T. Matsushima: Mutagen formation on  
nitrite treatment of indole compounds derived from  
indole- glucosinolate. Mutat. Res., 250, 169-174 (1991).  
45.	  H.G.M. Tiedink, J.A.R. Davies, N.A. Visser, W.M. F.  
Jongen, and L.W. van Broekhoven: The stability of the  
nitrosated products of indole, indole-3-acetonitrile,  
indole-3-carbinol and 4-chloroindole. Fd. Chem. Toxicol.  
27, 723-730 (1989).  
46.	  D.F. Birt, B. Walker, M.G. Tibbels, and E. Bresnick:  
Anti-mutagenesis and anti-promotion by apigenin,  
robinetin and indole-3-carbinol. Carcinogenesis 7, 959-
963 (1986) .  
47.	  B.C. Pence, F. Buddingh, and S.P. Yang: Multiple  
dietary factors in the enhancement of dimethylhydrazine  23 
carcinogenesis: main effect of indole-3-carbinol. J.  
Natl. Cancer Inst. 77, 269-276 (1986).  
48.	  B.C. Pence: Fecal mutagens and Bacteriodes fragilis  
levels in the feces of dimethylhydrazine-treated rats:  
influence of diet. Mutat. Res. 158, 53-60 (1985).  
49.	  G.S. Bailey, J.D. Hendricks, D.W. Shelton, J.E. Nixon,  
and N. Pawlowski: Enhancement of carcinogenesis by the  
natural anti-carcinogen indole-3-carbinol. J. Natl.  
Cancer Inst. 78, 931-934 (1987).  
50.	  D.J. Kim, K.K. Lee, B.S. Han, B. Ahn, J.H. Bae, and J.J.  
Jang: Biphasic modifying effect of indole-3-carbinol on  
diethylnitrosamine-induced preneoplastic glutathione S-
transferase placental form-positive liver cell foci in  
Sprague-Dawley rats. Jpn. J. Cancer Res., 86, 578-583  
(1994) .  
51.	  A. Poland, D. Palen, and E. Glover: 2,3,7,8-
Tetrachlorodibenzo-p-dioxin: segregation of toxicity  
with the Ah locus. Mol. Pharmacol. 17, 86-94 (1980).  
52.	  M. Gilner, J. Bergman, C. Cambillau, B. Fernstrom, and  
J-A. Gustafsson: Interactions of indoles with specific  
binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in  
rat liver. Mol. Pharmacol. 28, 357-363 (1985).  
53.	  L.F. Bjeldanes, J.Y. Kim, K.R. Grose, J.C. Bartholomew,  
and C.A. Bradfield: Aromatic hydrocarbon responsiveness- 
receptor agonists generated from indole-3-carbinol in  
vitro and in vivo: Comparisons with 2,3,7,8-
tetrachlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. 88,  
9543-9547 (1991).  
54.	  C.A. Bradfield and L.F. Bjeldanes: Modification of  
carcinogen metabolism by indolylic autolysis products of  
Brassica oleraceae. In "Nutritional and Toxicological  
Consequences of Food Processing" (M. Friedman, ed.), pp.  
153-163. Plenum Press, New York, 1991.  
55.	  B.N. Ames and L.S. Gold: Animal cancer tests and cancer  
prevention. Monogr. Natl. Cancer Inst. 12, 125-132  
(1992) .  
56.	  H. Liu, M. Wormke, S.H. Safe, L.F. and Bjeldanes:  
Indolo[3,2-b]carbazole: a dietary-derived factor that  
exhibits both antiestrogenic and estrogenic activity. J.  
Natl. Cancer Inst., 86, 1758-1765 (1994).  24 
57.	  G.H. Perdew and C.F. Babbs: Production of Ah receptor  
ligands in rat fecal suspensions containing tryptophan  
or indole-3-carbinol. Nutr. Cancer 16, 209-218 (1991).  
58.	  P.H. Jellinck, P.G. Forkert, D.S. Riddick, A.B. Okey,  
J.J. Michnovicz, and H.L. Bradlow: Ah receptor binding  
properties of indole carbinols and induction of hepatic  
estradiol hydroxylation. Biochem. Pharmacol., 45, 1129-
1136 (1993).  
59.	  H.G. Shertzer and M. Sainsbury: Chemoprotective and  
hepatic enzyme induction properties of indole and  
indenoindole antioxidants in rats. Fd. Chem. Toxicol.  
29, 391-400 (1991).  
60.	  L.W. Wattenberg: Chemoprevention of cancer. Cancer Res.  
45, 1-8 (1985).  
61.	  H.G. Shertzer: Indole-3-carbinol and indole-3-
acetonitrile influence on hepatic microsomal  
metabolism. Toxicol. Appl. Pharmacol. 64, 353-361  
(1982) .  
62.	  H.M. Wortelboer, E.C.M. van der Linden, C.A. de Kruif,  
B.J. Blaauboer, P.J. van Bladeren and H.E. Falke:  
Effects of indole-3-carbinol on biotransformation  
enzymes in the rat: in vivo changes in liver and small  
intestinal mucosa in comparison with primary hepatocyte  
cultures. Fd. Chem. Toxicol. 30, 589-599 (1992) .  
63.	  C.A. Bradfield and L.F. Bjeldanes: Effect of dietary  
indole-3-carbinol on intestinal and hepatic  
monooxygenase, glutathione S-transferase and epoxide  
hydrolase activities in the rat. Fd. Chem. Toxicol. 22,  
977-982 (1984) .  
64.	  C.A. Bradfield and L.F. Bjeldanes: Structure-activity  
relationship of dietary indoles: a proposed mechanism of  
action as modifiers of xenobiotic metabolism. J.  
Toxicol. Environ. Health 21, 31-35 (1987).  
65.	  C.A. Bradfield and L.F. Bjeldanes: Dietary modification  
of xenobiotic metabolism: Contribution of indolylic  
compounds present in Brassica oleraceae. J. Agric. Fd.  
Chem. 35, 896-900 (1987) .  
66.	  C.A. de Kruif, J.W. Marsman, J.C. Venekamp, H.E. Falke,  
J.Noordhoek, B.J. Blaauber and H.M. Wortelboer:  
Structure elucidation of acid reaction products of  25 
indole-3-carbinol: detection in vivo and enzyme  
induction in vitro. Chem. Biol. Interact. 80, 303-315  
(1991) .  
67.	  W.M.F. Jongen, R.J. Topp, H.G.M. Tiedink, and E.J.  
Brink: A co-cultivation system as a model for in vitro  
studies modulating effects of naturally occurring  
indoles on the genotoxicity of model compounds.  
Toxicol. In Vitro 1, 105-110 (1987)   .  
68.	  D.M. Stresser, G.S. Bailey, and D.E. Williams: Indole-3-
carbinol and beta-naphthoflavone.induction of aflatoxin  
B1 metabolism and cytochromes P-450 associated with  
bioactivation and detoxication of aflatoxin Bl in the  
rat. Drug Metab. Dispos., 22, 383-391 (1994).  
69.	  0. Vang, M.B. Jensen, and H. Autrup: Induction of  
cytochrome P4501A1 in rat colon and liver by indole-3-
carbinol and 5,6-benzoflavone. Carcinogenesis 11, 1259-
1269 (1990).  
70.	  O. Vang, M.B. Jensen, and H. Autrup: Induction of  
cytochrome P4501A1, IA2, IIB1, IIB2 and IIE1 by  
broccoli in rat liver and colon. Chem.-Biol. Interact.  
78, 85-96 (1991).  
71.	  J.G. Babish and G.S. Stoewsand: Effect of dietary  
indole-3-carbinol on the induction of the mixed- 
function oxidases of rat tissue. Fd. Cosmet. Toxicol.  
16, 151-155 (1978)   .  
72.	  A.B. Okey: Enzyme induction in the cytochrome P-450  
system. Pharmacol. Ther. 45, 241-298 (1990).  
73.	  K.R. Grose and L.F. Bjeldanes: Oligomerization of  
indole-3-carbinol in aqueous acid. Chem. Res. Toxicol.  
5, 188-193 (1992).  
74.	  J. Thesing: Beitrage zur chemie des indols, III.  
Metteil: Ober die einwirkung von alkali auf quartare  
salze des gramins. Chem Ber. 87, 692-699 (1954).  
75.	  N. Takahashi, R.H. Dashwood, L.F. Bjeldanes, G.S.  
Bailey, and D.E. Williams: Regulation of hepatic  
cytochrome P4501A by indole-3-carbinol: transient  
induction with continuous feeding in rainbow trout.  
Food Chem Toxicol 33, 111-120 (1995).  26 
76.	  H.G. Shertzer: Protection by indole-3-carbinol against  
covalent binding of benzo(a)pyrene metabolites to mouse  
liver DNA and protein. Fd. Chem. Toxicol. 21, 31-35  
(1983) .  
77.	  A.T. Fong, H.I. Swanson, R.H. Dashwood, D.E. Williams,  
J.D. Hendricks, and G.S. Bailey: Mechanisms of anti-
carcinogenesis by indole-3-carbinol: studies of enzyme  
induction, electrophile-scavenging, and inhibition of  
aflatoxin B1 activation. Biochem. Pharmacol. 39, 19-26  
(1990) .  
78.	  T.A. Eisele, G.S. Bailey, and J.E. Nixon: The effect of  
indole-3-carbinol, an aflatoxin B1 hepatocarcinoma  
inhibitor, and other indole analogs on the rainbow  
trout hepatic mixed function oxidase system. Toxicol.  
Lett. 19, 133-138 (1983).  
79.	  C. Ioannides and D.V. Parke: Induction of cytochrome  
P4501 as an indicator of potential chemical  
carcinogenesis. Drug Metab. Rev. 25, 485-501 (1993).  
80.	  R.T. Williams: Pathways in drug metabolism. In  
"Handbook of Experimental Pharmacology", vol. 28, pp.  
226-249. Springer-Verlag, Berlin, 1971.  
81.	  M.A. Morse and G.D. Stoner: Cancer chemoprevention:  
principles and prospects. Carcinogenesis 14, 1737-1746  
(1993).  
82.	  A.D. Salbe and L.F. Bjeldanes: Dietary influences on  
rat hepatic and intestinal DT-diaphorase activity. Fd.  
Chem. Toxicol. 24, 851-856 (1986).  
83.	  Y.-N. Cha, D.C. Thompson, H.S. Heine, and J.-H. Chung:  
Differential effects of indole, indole-3-carbinol and  
benzofuran on several microsomal and cytosolic enzyme  
activities in mouse liver. Kor. J. Pharmacol. 21, 1-11  
(1985) .  
84.	  D.M. Stresser, D.E. Williams, L.I. McLellan, T.M.  
Harris, and G.S. Bailey: Indole-3-carbinol induces a rat  
liver glutathione transferase subunit (Yc2) with high  
activity toward  aflatoxin B1 exo-epoxide. Association  
with reduced levels of hepatic aflatoxin-DNA adducts in  
vivo. Drug Metab. Dispos., 22, 392-399 (1994).  
85.	  V.L. Sparmins, P.L. Venegas, and L.W. Wattenberg:  
Glutathione S-transferase activity: enhancement by  
compounds inhibiting chemical carcinogenesis and by  27 
dietary constituents. J. Natl. Cancer Inst. 68, 493-496  
(1982).  
86.	  D.P. Danger,W.S. Baldwin, and G.A.  LeBlanc:  
Photoaffinity labeling of steroid hormone-binding  
glutathione- S-transferases with [3]methyltrienolone.  
Inhibition of steroid binding activity by the  
anticarcinogen indole-3-carbinol. Biochem. J. 288, 361-
367 (1992).  
87.	  L.M. Valsta, J.D. Hendricks and G.S. Bailey: The  
significance of glutathione conjugation for aflatoxin  
B1 metabolism in rainbow trout and coho salmon. Fd.  
Chem. Toxicol. 26, 129-135 (1988)   .  
88.	  S. Larsen-Su and D.E. Williams: Dietary indole-3-
carbinol inhibits FMO activity and the expression of  
flavin-containing monooxygenase form 1 in rat liver and  
intestine. Drug Metab Dispos 24, 927-931 (1996).  
89.	  N. Takahashi, R.H. Dashwood, L.F. Bjeldanes, D.E.  
Williams, and G.S. Bailey: Mechanisms of indole-3-
carbinol (I3C) anticarcinogenesis: inhibition of  
aflatoxin Bl-DNA adduction and mutagenesis by I3C acid  
condensation products. Food Chem Toxicol 33, 851-857  
(1995)  .  
90.	  H.G. Shertzer, M.L. Berger, and M.W. Tabor:  
Intervention in free radical mediated hepatotoxicity  
and lipid peroxidation by indole-3-carbinol. Biochem.  
Pharmacol. 37, 333-338 (1988).  
91.	  M.B. Arnao, J. Sanchez-Bravo, M. and Acosta: Indole-3-
carbinol as a scavenger of free radicals. Biochem.  
Molec. Biol. Internatl. 34, 1125-1134 (1996).  
92.	  M.N. Preobrazhenskaya, V.M. Bukhman, A.M. Korolev, and  
S.A. Efimov: Ascorbigen and other indole-derived  
compounds from Brassica vegetables and their analogs  as  
anticarcinogenic and immunomodulating agents. Pharmacol.  
Ther. 60, 301-13 (1993)   .  
93.	  T. Niwa, G. Swaneck, and H.L. Bradlow: Alterations in  
estradiol metabolism in MFC-7 cells induced by treatment  
with indole-3-carbinol and related compounds. Steroids  
59, 523-527 (1994).  
94.	  H.L. Bradlow, J.J. Michnovicz, M. Halper, D.G.  
Miller,G.Y. Wong, and M.P. Osborne: Long-term responses  28 
of women to indole-3-carbinol or a high fiber diet.  
Cancer Epidemiol. Biomarkers Prey. 3, 591-595 (1994).  
95	  A. Suto, H.L Bradlow, G.Y. Wong, M.P. Osborne, and N.T.  
Telang: Persistent estrogen responsiveness of ras  
oncogene-transformed mouse mammary epithelial cells.  
Steroids, 57, 262-268 (1992).  
96.	  W.S. Baldwin and G.A. LeBlanc: The anti-carcinogenic  
plant compound indole-3-carbinol differentially  
modulates P450 mediated steroid hydroxylase activities  
in mice. Chem.-Biol. Interact., 83, 155-169 (1992).  
97.	  D.W. Sepkovic, H.L. Bradlow, J. Michnovicz, S.  
Murtezani, I. Levy, and M.P. Osborne: Catechol estrogen  
production in rat microsomes after treatment with  
indole-3-carbinol, ascorbigen, or b-naphthoflavone: a  
comparison of stable isotope dilution gas  
chromatography-mass spectrometry and radiometric  
methods. Steroids 59, 318-323 (1994).  
98.	  0. Nunez, J.D. Hendricks, D.N. Arbogast, A.T. Fong, B.C.  
Lee, and G.S.Bailey: Promotion of aflatoxin B1  
hepatocarcinogenesis in rainbow trout by 17b-estradiol.  
Aquatic. Toxicol. 15, 289-302 (1989).  
99.	  J.D. Yager and R. Yager: Oral contraceptive steroids as  
promoters of hepatocarcinogenesis in female Sprague- 
Dawley rats. Cancer Res. 40, 3680-3685 (1980).  
100. J.D. Yager, H.A. Campbell, D.S. Longnecker, B.D.  
Roebuck, and M.C. Benoit: Enhancement of  
hepatocarcinogenesis in female rats by ethinyl estradiol  
and mestranol but not estradiol. Cancer Res. 44, 3862-
3869 (1984).  
101. I.R. Wanless and A. Medline: Role of estrogens as  
promoters of hepatic neoplasia. Lab. Invest. 46, 313-319  
(1982) .  
102. M. Ghia and E. Mereto: Induction and promotion of gamma-
glutamyltranspeptidase-positive foci in the liver of  
female rats treated with ethinyl estradiol, clomiphene,  
tamoxifen and their associations. Cancer Lett. 46, 195-
202 (1989).  
103. Y.P. Dragan, Y.D. Xu, and H.C. Pitot: Tumor promotion as  
a target for estrogen/antiestrogen effects in rat  
hepatocarcinogenesis. Prev. Med. 20, 15-26 (1991).  29 
104. D. Campen, R. Maronpot, and G. Lucier: Dose-response  
relationships in promotion of rat hepatocarcinogenesis  
by 17 alpha-ethinylestradiol. J. Toxicol. Environ.  
Health 29, 257-268 (1990).  
105. J.J. Li, H. Kirkman, and S.A. Li: Synthetic estrogens  
and liver cancer: risk analysis of animal and human  
data..Hormonal Carcinogenesis: Proc. 1st Int. Symp. New  
York: Springer-Verla, 217-234 (1992).  
106. A. Tavanti, E. Negri, F. Parazzini, S. Franceschi, and  
C. LaVecchia: Female hormone utilization and risk of  
hepatocellular carcinoma. Br. J. Cancer 67, 635-637  
(1993).  
107. J.G. Christensen and G.A. LeBlanc: Reversal of multidrug  
resistance in vivo by dietary administration of the  
phytochemical indole-3-carbinol. Cancer Res. 56, 574-581  
(1996) .  
108.X. Ge, S. Yannis, G: Rennert, N. Gruener, and F.A. Fares:  
3,3'-Diindolylmethane induces apoptosis in human cancer  
cells. Biochem. Biophys. Res. Commun. 228, 153-158  
(1996) .  
109. S.E. Dunn and G.A. LeBlanc: Hypocholesterolemic  
properties of plant indoles: Inhibition of acyl-
CoA:cholesterol acyltransferase activity and reduction  
of serum LDL/VLDL cholesterol levels by glucobrassicin  
derivatives. Biochem. Pharmacol. 47, 359-364 (1994).  
110. N. Takahashi, D.M. Stresser, D.E. Williams, and G.S.  
Bailey: Induction of hepatic CYP1A by indole-3-carbinol  
in protection against aflatoxin B1 hepatocarcinogenesis  
in rainbow trout. Food Chem. Toxicol. 33, 841-850  
(1995) .  
111. D.L. Eaton and E.P. Gallagher: Mechanisms of aflatoxin  
carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 34, 135-
172 (1994).  30 
Chapter 2  
a-NAPHTHOFLAVONE (ANF) ACTS AS A WEAK Ah RECEPTOR  
AGONIST IN VIVO AND ANTAGONIST IN VITRO  
IN RAINBOW TROUT  
A. Oganesian, J.D. Hendricks and D.E. Williams  
Toxicology Program, Marine/Freshwater Biomedical Sciences  
Center, Department of Food Science and Technology, Oregon  
State University, Corvallis OR.  31 
ABSTRACT 
ANF, a synthetic flavone, is an Ah receptor (AhR)  
antagonist and partial agonist in mammals, capable of blocking  
TCDD-mediated biological effects in vitro and in vivo. Our aim  
was to study the involvement of the AhR in tumor promotion in  
the trout model by utilizing ANF as a blocking agent. We  
report here the results of a tumor study designed to assess  
the potential for dietary ANF to block promotion of  
carcinogenesis by dietary 0-naphthoflavone (BNF) as a test of  
whether the latter may be Ah receptor-dependent.  
The potency of ANF as an Ah receptor antagonist was observed  
in vitro in liver slices. When slices were exposed to ANF  
before, during, and after BNF was added into medium, CYP1A  
induction was lower compared to levels seen in slices exposed  
to BNF alone. These results confirm reports in the literature  
that ANF can act as an Ah receptor antagonist and block AhR-
mediated biological responses. In the tumor study, trout were  
initiated as fry with 1.5 ppm 7,12-dimethylbenz[a]anthracene  
(DMBA). Experimental diets, containing 200 ppm ANF, BNF, or  
both were given after 3 months of control diet. Fish were  
sampled for liver, stomach and swim bladder tumors at 11  
months. Significant promotion of hepatic carcinogenesis was  
observed for both the BNF (27.5 % tumor incidence versus 8 %)  
and ANF-fed (18 % versus 8 %) groups. An even greater  32 
enhancement (39% incidence) was observed with a combined ANF-
BNF diet (200 ppm each). A short-term in vivo experiment was  
conducted to determine the potency of ANF as an Ah receptor  
agonist and/or antagonist. Trout were injected ip with 0,  0.5,  
10, 20, or 40 mg/kg ANF daily for 4 days. All ANF-treated  
groups were then administered either 0 or 500 ppm BNF in the  
diet for a period of 1 week. ANF alone induced CYP1A and the  
groups given dietary BNF exhibited additive responses. The  
additivity of ANF and BNF in inducing trout CYP1A is  
consistent with the tumor enhancement data and supports a role  
for the Ah receptor. Hence, in trout,  (as in mammals) ANF can  
function as a partial agonist and is not a suitable choice for  
blocking Ah receptor-dependent carcinogenesis in this model.  33 
INTRODUCTION 
The aryl hydrocarbon receptor (Ah receptor) is a  
cytosolic protein with a basic helix-loop-helix region which  
mediates many biochemical and toxic responses to a number of  
xenobiotics. During the Ah receptor-mediated induction of  
different enzymes a sequence of events takes place (1-5).  
Foreign chemical inducers, such as 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD), 3-methylcholanthrene or B-naphthoflavone  
(BNF) bind to the Ah receptor to form an inducer-receptor  
complex which then translocates into the nucleus and, after  
forming a dimer with the Ah receptor nuclear translocator  
protein, binds to dioxin-responsive elements (DREs)  (or  
xenobiotic-responsive elements (XREs)) triggering the enhanced  
transcription of various genes including CYP1A1 and CYP1A2.  
These enzymes are responsible for catalyzing various reactions  
in drug metabolism and procarcinogen activation (4).  
We have been characterizing properties of the Ah  
receptor in the trout (Oncorhynchus mykiss) model as an  
initial step towards understanding possible Ah receptor  
mediated tumor promotion. In particular, we are exploring the  
potential for blocking Ah receptor-dependent promotion by the  
antagonist a-naphthoflavone (ANF). The objective of this study  
was to attempt to use the antagonistic properties of ANF to  
inhibit Ah receptor-mediated promotion of chemically-induced  34 
carcinogenesis by BNF in the rainbow trout tumor model. Post- 
initiation dietary BNF is reported to promote chemical  
carcinogenesis in trout (6). If proven to be able to inhibit  
promotion by the Ah receptor agonist BNF, ANF could be used as  
a blocking agent to examine the mechanism(s) of action of  
other promoters, namely agents believed to act through the Ah  
receptor pathway, including indole-3-carbinol (I3C)(7, 8).  
In addition to being an effective antagonist, ANF can  
also function as a partial agonist depending on the dose and  
the conditions of the experiment. Here we analyzed ANF potency  
as (ant)agonist in both in vitro and in vivo experimental  
designs, including a dose-response experiment with both ANF  
and BNF. As will be shown later, ANF acts as an antagonist of  
the Ah receptor in vitro (liver slices) but as a weak agonist  
in vivo in both short- and long-term (tumor study)  
experiments.  35 
MATERIALS AND METHODS  
Materials  
All chemicals were purchased from Sigma Chem. Co.  (St.  
Louis, MO) unless otherwise noted. Antibody for immunoblotting  
against CYP1A was generously provided by Dr. Donald Buhier of  
Oregon State University.  
Animals and treatments  
Rainbow trout (Oncorhynchus mykiss) were hatched and  
reared at the Oregon State University Food Toxicology and  
Nutrition Laboratory in 14°C (average temperature) flowing  
well water.  
For the tumor study, approximately 1,600 fry were  
initiated with 1.5 ppm DMBA by immersion for 5 hours. Sham- 
exposed embryos were exposed to vehicle alone (0.01 %  
ethanol) and served as non-initiated controls. After  
initiation, fry were fed Oregon Test Diet (OTD), a  
semipurified, casein-based diet (20) for three months, after  
which trout were divided into experimental treatment groups  
and fed OTD diets containing 0 or 200 ppm ANF, BNF, or both  
ANF and BNF (200 ppm each). Once on experimental diets,  
trout were fed ad lib (2.8-5.6 % body weight), five times  
per week. ANF and BNF were added to the oil portion of the  
diets during preparation. Diets were prepared biweekly and  
stored frozen at -20°C until 2-4 days prior to feeding when  36 
diets were allowed to thaw at 4°C. Each treatment group  
contained 200 fish housed 100 per tank'in 100-gallon  
continuous flow tanks. At 11 months of age trout were  
sampled for liver, stomach and swim bladder tumors while  
still sexually immature. Several randomly selected livers  
from each group were frozen and later analyzed for CYP1A  
induction.  
In a short-term dose-response experiment, 7-8 month old  
trout were injected ip with ANF or BNF daily for four days  
at 0  (vehicle  dimethylsulfoxide (DMSO)), 0.2, 0.5, 2,  5,  
15, 30, or 75 mg/kg. On day 5 fish were sacrificed and  
livers instantly frozen for preparation of microsomes. A  
second dose-response study, involving a wider dose range  
(0.05-75 mg/kg), was carried out for measuring EROD  
(ethoxyresorufin-O-deethylase) activity. In another  
experiment, trout were pretreated with ip injection of ANF  
(daily for 4 days), and BNF was thereafter given in the diet  
at 500 ppm for 1 week, after which trout were sacrificed and  
livers collected for preparation of microsomes.  
In vitro dose-response, and ANF-BNF co-, pre-, and post- 
incubation studies with trout liver slices were conducted with  
fresh precision-cut slices. Slices were prepared using a  
Krumdieck tissue slicer and incubated in the Hanks modified  
salts buffer (supplemented with 1  % BSA and 50 mg/ml  
gentamicin) containing ANF or BNF at concentrations of 200  37 
for ANF and 40 1.1M for BNF for the first 24 h. ANF was  
administered either with BNF from the start of incubation, or  
6 h prior and/or after BNF addition into medium. Slices were  
incubated under sterile conditions in 95% 02/5% CO2 atmosphere  
at 14° C for 48 hours, and then homogenized and analyzed for  
CYP1A protein levels by immunoblotting.  
Preparation of hepatic microsomes and enzyme assays  
Livers were homogenized in 4-5 volumes of ice cold 0.1 M  
potassium phosphate buffer (pH 7.4) containing 0.15 M KC1,  
mM EDTA and 1 mM phenylmethylsulfonyl fluoride. Microsomes  
were prepared by differential centrifugation according to  
Guengerich (9). The supernatant from a 10,000 g centrifugation  
of liver homogenate was subjected to centrifugation at 100,000  
g. The resulting pellet was washed with potassium  
pyrophosphate buffer (0.1 M, pH 7.4,  1 mM EDTA,  1 mM PMSF),  
centrifuged at 100,000 g, and the pellet resuspended in  
homogenization buffer containing 20 % glycerol to obtain  
microsomes.  
Protein determinations were made according to the method  
of Lowry et a/.(10).  
The 7-ethoxyresorufin-O-deethylase (EROD) assay was  
modified from Pohl and Fouts (11) using liver microsomes at  
25° C.  
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The  total  specific  content  of  cytochrome  P-450  was  
measured  spectrophotometrically  by  the  reduced-CO  versus  
oxidized-CO difference spectrum (9).  
Electrophoresis and immunoblotting  
CYP1A levels were examined in liver microsomal  
fractions, prepared as described above. Proteins were  
separated by sodium dodecyl sulfate-polyacrylamide gel  
electrophoresis (SDS-PAGE) on 8 % acrylamide gels (12) and  
electrophoretically transferred onto nitrocellulose (Bio-Rad  
Trans-Blot). Blots were probed with rabbit polyclonal  
antibodies to trout CYP1A, followed by a horseradish  
peroxidase-linked secondary antibody. Proteins were detected  
using an Amersham ECL chemiluminescence kit (Amersham Corp.,  
Arlington Heights, IL). Western blots were scanned on a  
flatbed HP Scanjet IIcx scanner. Densitometry was performed  
with the public domain software NIH Image, version 1.57  
(written by Wayne Rasband at the US National Institutes of  
Health).  
Necropsy and histopathology  
At termination, fish were sacrificed by a combination of  
deep anesthesia, resulting from an overdose of tricaine  
methane sulfonate (MS-222), and bleeding, after cutting the  
gill arches on the left side of the fish. Tissues were  
inspected for neoplasms under a dissecting microscope. After  
marking and recording the size and location of all surface  39 
tumors, the livers were fixed in Bouin's solution for 2-7  
days. All livers were then cut into one mm slices with a razor  
blade to retrieve previously marked tumors and to locate any  
internal, previously unseen tumors. At least one piece of  
liver from each tumor-bearing fish was then processed by  
routine histological procedures, and stained with hematoxylin  
and eosin for histological evaluation (21).  
Statistical analysis  
Only fish from initiated groups had tumors. Statistical  
differences between treatment groups were assessed by  
logistic regression using GENMOD procedure, SAS System for  
Windows, version 6.12, SAS Institute, Inc., Cary, NC).  
Differences between groups were tested using one-way  
analysis of variance, followed by the least significant  
difference multiple comparison test using the statistical  
software package, Statgraphics (version 5.0),  (Statistical  
Graphics Corporation, Princeton, New Jersey). A probability  
value of less than 0.05 was considered significant.  40 
RESULTS  
In vitro, ANF did antagonize CYP1A induction by BNF in  
liver slices when administered concurrently with,  6 hours  
before, or after BNF addition into medium. ANF alone induced  
CYP1A at weaker levels compared to BNF, but in all cases when  
co-incubated with BNF, induction was seen at levels  
significantly lower when compared to BNF-alone samples  
(Fig. 2.1).  
In the short-term dose-response experiment both ANF and  
BNF exhibited induction of total P-450 in the liver (Fig. 2.2)  
with BNF exhibiting greater potency. Induction somewhat faded  
at higher doses (15 mg/kg and higher), perhaps due to  
toxicity. Mortality (10 %) was observed at 30 and 75 mg/kg.  
Induction of EROD activity, which represents CYP1A, was  
significant only at 2 mg/kg for ANF, whereas, BNF  
significantly induced across the whole range of treatment  
doses in a dose-dependent fashion (Fig. 2.3).  
The tumor incidences and values of odds ratio versus  
initiated controls are presented in Table 2-I. Statistically  
significant promotion was observed for all treatment groups,  
with the combined ANF and BNF diet exhibiting higher tumor  
incidence than the group fed BNF only. The incidence of  
multiple tumors was significantly higher in groups fed BNF and  
the combined BNF-ANF diet. Hepatic CYP1A levels (measured in  41 
microsomes) were induced in all treatment groups at levels  
consistent with tumor incidences (Fig. 2.4).  
The ability of ANF to act as an agonist or antagonist in  
vivo after short-term exposure was analyzed by measuring CYP1A  
levels in hepatic microsomes at the conclusion of the  
experiment involving ANF-pretreatment followed by dietary BNF.  
Additivity of CYP1A induction was apparent in the treatment  
group featuring pretreatment with a high dose of ANF  
(Fig. 2.5). No antagonism by ANF, as evidenced by inhibition  
of BNF-mediated induction, was detected in this short-term in  
vivo study.  42 
DISCUSSION  
ANF and BNF, both synthetic compounds, have been used in  
research studying the mechanism(s) of Ah receptor mediated  
toxicity. BNF binds to the Ah receptor and is used as a  
classic agonist. ANF, however, was originally proposed as an  
antagonist of the Ah receptor and is suggested to exhibit  
antagonism by binding to the Ah receptor and changing the  
conformation of the protein which prevents it from binding to  
DREs (13-16) .  
We are investigating the mechanism(s) of carcinogenesis  
promotion by indole-3-carbinol, a plant secondary metabolite  
common in crucifers. Some of the I3C-derived condensation  
products possess relatively high affinity for the Ah receptor  
and induce CYP1A (7,  8, 17-19) leading to speculation that  
promotion by I3C could be due to the Ah-receptor mediated  
pathway. The choice of ANF as a candidate compound for  
inhibiting Ah-receptor mediated tumor promotion was made with  
the hypothesis that if successful, it could be used to test  
whether carcinogenesis promotion by I3C is indeed mediated  
through the Ah receptor.  
ANF, however, is also known to have weak agonistic  
activity in mammalian systems under certain conditions (14,  
15). This was confirmed in our study in trout. ANF itself did  
induce CYP1A both in vivo after long-term (tumor study) and  43 
short-term exposure, and in vitro (liver slices). Dietary ANF  
also resulted in promotion of hepatocarcinogenesis, however,  
not as potently as BNF, and when given concurrently with BNF,  
promotion was enhanced in an apparently additive manner. The  
antagonism by ANF was observed only in vitro in liver slices  
and at concentration (200 4M) exceeding that of the agonist  
BNF (40 4M, derived from a dose-response experiment in slices  
and shown to be the maximum CYP1A inducing concentration).  
Our findings suggest that ANF is not a good choice for  
an antagonist for blocking promotion of carcinogenesis by Ah  
agonists (such as BNF). We are currently examining the  
potential of a reportedly pure AhR antagonist 4'-amino-3'-
methoxyflavone, provided by Dr. Stephan Safe (University of  
Texas) in vitro with trout liver slices. If successful, future  
studies in vivo will test the role of the AhR in I3C-dependent  
promotion of hepatocarcinogenesis in trout.  44 
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fish throughout the study.  Table 2-I. Promotion of DMBA-initiated hepatocarcinogenesis by ANF and BNF.  
Only data from inititated fish are presented (no tumors were observed in  
vehicle-exposed fish).  
Initiation Diet  # fish	  tumor  incidence of  odds ratio  
incidence(%)  multiple tumors'  vs control  
(95% c.i.)  
DMBA2  control  200  8.0  12.5  1  
DMBA  ANF  200  18.0*  11.1  2.52  (1.35-4.72)  
DMBA  BNF  200  27.0*  29.6*  4.36  (2.40-7.93)  
DMBA  ANF+BNF3  192  39.1*  33.3*  6.89  (3.84-12.39)  
1  % tumor bearing fish with multiple tumors  
2  initiation with 1.5 ppm DMBA as fry,  5 h immersion  
3  compounds were given in diet at 200 ppm each  
represents statistically significant difference from positive control (p < 0.05).  20 
Effects of ANF on CYP1A Induction by BNF  
in Trout Liver Slices I  
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Figure 2.1. Antagonism of BNF CYP1A induction by ANF in vitro in trout liver slices.  
Inhibition of CYP1A induction by BNF with pre-, co-, and post-treatment with  
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Figure 2.4. Induction of hepatic microsomal CYP1A in the trout tumor study. DMBA-initiated  
trout were fed diet containing 0, or 200 ppm BNF, ANF, or both.  -
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ABSTRACT  
Indole-3-carbinol (I3C)*, a metabolite of  
glucobrassicin found in cruciferous vegetables, is  
documented to act as a modulator of carcinogenesis and,  
depending on timing and dose of administration, it may  
promote hepatocarcinogenesis in some animal models. In this  
study we demonstrate that, when given post-initiation,  
dietary I3C promotes aflatoxin B1 (AFB1)-induced  
hepatocarcinogenesis in the rainbow trout model at levels as  
low as 500 ppm. Trout embryos (approximately 9,000) were  
initiated with 0, 25, 50, 100, 175, or 250 ppb AFB1 with a  
30 min immersion. Experimental diets containing 0, 250, 500,  
750, 1000, or 1250 ppm I3C were administered starting at 3  
months and fish were sampled for liver tumors at 11-13  
months. Promotion at the level of tumor incidence was  
statistically significant for all dietary levels, except 250  
ppm. Relative potency for promotion markedly increased at  
dietary levels above 750 ppm. We propose that more than one  
mechanism could be involved in promotion and that both  
estrogenic and Ah receptor-mediated pathways could be  
active. The estrogenicity of I3C, measured as its ability to  
induce vitellogenin (an estrogen biomarker in oviparous  
vertebrates) was evident at the lowest dietary level (250  
ppm), whereas, CYP1A (a P450 isozyme induced through the Ah  56 
receptor pathway) was not induced until dietary levels of  
1000 ppm. Therefore, at lower dietary levels, promotion by  
I3C in this model could be explained by estrogenic  
activities of I3C acid derivatives, as it is known that  
estrogens promote hepatocarcinogenesis in trout. Much  
stronger promotion was observed at high dietary I3C levels  
(1000 and 1250 ppm), at which levels both CYP1A and  
vitellogenin were induced.  
*Abbreviations: I3C, indole-3-carbinol (3-indolemethanol);  
AFB1, aflatoxin B1; OTD, Oregon Test Diet; CYP, cytochrome  
P450; VG, vitellogenin; MS-222, tricaine methane sulphonate.  57 
INTRODUCTION 
Indole-3-carbinol (I3C), a plant secondary metabolite  
found in cruciferous vegetables such as broccoli,  
cauliflower, Brussels sprouts, etc and is available to the  
general public for purchase as a dietary supplement in  
various forms over the internet as well as through health  
food stores and distribution networks.  
Dietary I3C has been documented to inhibit  
tumorigenesis (1-4) in various target organs, including  
mammary tissue (5), liver (6,  7), endometrium (8), lung (9-
12), and other target organs (13,  14) in various animal models  
and is currently being evaluated in human clinical trials as a  
potential chemopreventive agent against breast and ovarian  
cancers (15). The chemopreventive properties of I3C are  
proposed to occur through several possible mechanisms,  
including the alteration of estrogen metabolism (16-21).  
Furthermore, I3C is reported to inhibit glutathione-S-
transferase-mediated steroid binding activity (22), act as a  
scavenger of free radicals (23), modulate the activity of  
multidrug resistance (24), and alter the expression of various  
phase I and phase II drug-metabolizing enzymes (20, 25-28)  
contributing to detoxification of carcinogenic compounds.  
Upon dietary intake, I3C undergoes acidic condensation  
reactions in the stomach, yielding various derivatives  58 
believed to be responsible for its biological effects (29-33).  
Some of the condensation products of I3C have antiestrogenic  
as well as estrogenic activities (29) and also possess  
relatively high affinity for binding to the Ah receptor (34,  
35). A major condensation product, the dimer 3,3'-
diindolylmethane (I33'), is capable of inducing apoptosis in  
human cancer cells (36) and is an effective inhibitor in vitro  
of cytochromes P450 (35, 37, 38). Carcinogenesis  
chemoprevention properties of dietary I3C in most of the  
models are evident when it is administered concurrently with  
the carcinogen or prior to initiation. Yet there are reports  
that, when given after initiation (promotion-progression  
stage), I3C can enhance carcinogenesis (1,  3, 7). There is  
also some evidence that I3C may be mutagenic when co-
adminiStered in diet along with nitrites (39).  
Earlier studies (3,  7) have documented the ability of  
I3C to promote AFB1- initiated hepatocarcinogenesis at  
relatively high dietary levels (1000 ppm). The objective of  
this study was to evaluate the tumor promoting properties of  
I3C at relatively low dietary levels, across a wide range of  
initiator doses, and to investigate the possibility of a  
threshold for promotion within these range of doses. We report  
that I3C promoted significantly in all treatment groups except  
250 ppm. We further demonstrate, that the estrogenicity of I3C  
is evident at the lowest dietary levels at which point CYP1A  59 
was not induced. Perhaps, at the lower dietary I3C treatment  
groups, the mechanism for hepatocarcinogenesis promotion  
involves estrogenic pathways, as it is known that estrogens  
promote chemically-induced hepatocarcinogenesis in the trout  
(40). The Ah receptor-mediated pathway could play a role in  
promotion at higher dose treatment groups (above 750 ppm),  
where the ability of I3C to induce CYP1A was evident. It is  
documented that certain estrogens (oral contraceptives) are  
implicated in promotion of hepatic adenomas and carcinomas in  
humans (41, 42). Based on observations from this study and the  
relevance of estrogens in human cancer risk, we suggest that  
dietary I3C supplementation be approached with caution until  
the mechanism(s) of hepatocarcinogenesis promotion in the  
trout and rat and the implications for human cancer risk are  
fully understood.  60 
MATERIALS AND METHODS  
Materials  
AFB1 was purchased from Sigma Chem. Co.  (St. Louis, MO).  
I3C was purchased from Aldrich Chem. (Milwaukee, WI). Rabbit  
polyclonal antibodies against vitellogenin and CYP1A were  
generously provided by Dr. Donald Buhler (Oregon State  
University).  
Animals and treatments  
Rainbow trout (Oncorhynchus mykiss) were hatched and  
reared at the Oregon State University Food Toxicology and  
Nutrition Laboratory in 14°C (average temperature) flowing  
well water. Approximately 9,000 embryos were initiated with  
25, 50, 100, 175, or 250 ppb AFB1 for 30 min. Sham-exposed  
embryos were exposed to vehicle alone (0.01 % ethanol) and  
served as non-initiated controls. After hatching, fry were  
fed Oregon Test Diet (OTD), a semipurified, casein-based  
diet (43) for three months, after which trout were randomly  
(within initiator treatment groups) divided into  
experimental treatment groups and fed OTD diets containing  
0, 250, 500, 750, 1000 or 1250 ppm I3C. Once on experimental  
diets, trout were fed ad lib (2.8-5.6 % body weight), five  
times per week. I3C was added to the aqueous portion of the  
diets during preparation. Diets were prepared biweekly and  
stored frozen at -20°C until 2-4 days prior to feeding when  61 
diets were allowed to thaw at 4°C. Each treatment group  
contained 200-400 fish (larger numbers of fish were used for  
low-dose initiated groups fed lower levels of I3C in diet)  
housed approximately 100 per tank in replicate 100-gallon  
continuous flow tanks. At 11 months of age trout were  
sampled for liver tumors while still sexually immature.  
Because of the large number of fish involved, the sampling  
was carried out over 66 days (all groups were switched to  
OTD diets during sampling). Blood was drawn from the caudal  
vein (in order to examine for vitellogenin induction), and,  
at the start of the sampling period (while trout were still  
on I3C diets), 10 livers from each group were frozen and  
later analyzed for CYP1A induction.  
Electrophoresis and immunoblotting  
Vitellogenin levels were determined in plasma from  
trout. CYP1A levels were examined in liver microsomal  
fractions, prepared as previously described (44). Proteins  
were separated by sodium dodecyl sulfate-polyacrylamide gel  
electrophoresis (SDS-PAGE) on 8 % acrylamide gels (45) and  
electrophoretically transferred onto nitrocellulose (Bio-Rad  
Trans-Blot). Blots were probed with rabbit polyclonal  
antibodies to salmon vitellogenin (for plasma) and trout CYP1A  
(liver microsomes) followed by a horseradish peroxidase-linked  
secondary antibody. Proteins were detected using an Amersham  62 
ECL chemiluminescence kit (Amersham Corp., Arlington Heights,  
IL). Western blots were scanned on a flatbed HP Scanjet IIcx  
scanner. Densitometry was performed with the public domain  
software NIH Image, version 1.57 (written by Wayne Rasband at  
the US National Institutes of Health).  
Necropsy and histopathology  
At termination, fish were sacrificed by a combination of  
deep anesthesia, resulting from an overdose of tricaine  
methane sulfonate (MS-222), and bleeding, after cutting the  
gill arches on the left side of the fish. The fish were  
weighed, livers removed and weighed, and the livers inspected  
for neoplasms under a dissecting microscope. After marking and  
recording the size and location of all surface tumors, the  
livers were fixed in Bouin's solution for 2-7 days. All livers  
were then cut into one mm slices with a razor blade to  
retrieve previously marked tumors and to locate any internal,  
previously unseen tumors. At least one piece of liver from  
each tumor-bearing fish was then processed by routine  
histological procedures, and stained with hematoxylin and  
eosin for histological evaluation. Neoplasms were classified  
by the criteria of Hendricks et. al.  (46). The relative  
numbers of different tumor types were thus based on a random,  
non-exhaustive sample of all the tumors that occurred. When  
multiple tumors occurred on a tissue slide, only the largest  
or the most frequently occurring tumor type was recorded.  63 
Statistical analysis  
Tumor incidence and incidence of multiple tumors in 78  
tanks containing initiated fish, was modeled by logistic  
regression, allowing for possible overdispersion (GENMOD  
procedure, SAS System for Windows, version 6.12, SAS  
Institute, Inc., Cary, NC). Variation between replicate tanks  
provided the initial estimated multiplicative dispersion  
factor. Parsimonious models were chosen based on the results  
of drop-in-deviance quasi-likelihood F-tests.  
Relative potency(RP) for promotion was calculated using  
RP=TDxj/TDx0, where "x" is the tumor incidence being compared  
(e.g. 50%), TDx0 is the dose of AFB1 needed to yield that  
tumor incidence in the 0 ppm I3C (initiate control) group,  
and TDxi is the dose of AFB1 that is required to produce that  
tumor incidence in the group receiving "i" ppm I3C. Estimates  
and confidence intervals were generated from logistic  
regression modeling results (log(relative potency)=difference  
between estimated intercepts divided by estimated slope) with  
the delta method used to calculate standard errors.  64 
RESULTS  
A dose response was observed for tumor incidence with  
increasing I3C levels in diet(Table 3 -I), Fig. 3.1. The  
tumor promotional effects of I3C were apparent at all levels  
across the initiator dose range (p<0.01) except for 250 ppm  
(significant for only the highest AFB1 groups, fed 250 ppm  
I3C). (Table 3-11). Based on these observations, the  
existence of a threshold for promotion of AFB1-
hepatocarcinogenesis by dietary I3C could neither be  
demonstrated, nor discounted  
Overall, the variation between replicate tanks was 1.92  
times larger than expected under the binomial error assumption  
indicating significant overdispersion (p<0.0001). The  
variation was greatly reduced by adding a continuous covariate  
for day of sampling (p<0.0001). After adjusting for the  
covariate the remaining variation between replicate tanks was  
only 1.24 times larger than expected under the binomial error  
assumption (test for overdispersion, p=0.11). Therefore the  
conclusions for the more conservative overdispersed model used  
here will be similar to the conclusions from a model assuming  
only binomial variation.  
The relative potency (RP) or promotion of AFB1-
hepatocarcinogenesis by dietary I3C is depicted in Fig. 3.2.  
There is a marked increase in the value for the RP with  65 
dietary I3C increasing above 750 ppm At levels below 750 ppm  
promotion is evident, however, with lower potency.  
The spectrum of tumor types was the same as previously  
observed (47), and included malignant and benign neoplasms  
of hepatocellular, cholangiocellular, or mixed  
hepato/cholangio origin. There was a difference in this  
experiment, however, since the hepatocellular carcinoma type  
was the predominant tumor rather than the mixed carcinoma  
observed in previous studies (40, 48, 49). Some variability  
in the relative percentages of the various tumor types  
occurred, particularly in the lower incidences seen at the  
low dose levels, but the trend was the same throughout  
(Table 3-111 tumor type summary). The overall averages of  
tumor occurrences were as follows: hepatocellular carcinoma,  
56.5%; mixed hepatocellular-cholangiocellular carcinoma,  
29.4%; cholangiocellular carcinoma, 1.2%; hepatocellular  
adenoma, 8.7%; mixed adenoma, 0.3%; and cholangiocellular  
adenoma, 3.9%. With the exception of an approximate reversal  
of the percentages of the first two tumor types, everything  
else was very consistent with what has been seen previously.  
No obvious reason for this change in tumor type is apparent.  
The potential of I3C to function as an estrogen in  
trout was assessed by measuring plasma vitellogenin (VG)  
levels (50). No VG was detected in controls (0 ppm I3C)  
(Fig. 3.3). For the groups fed 250 ppm 13C, weak VG protein  66 
bands were seen on the film, however, the levels were below  
the resolution limit for quantification by scanning  
densitometry. VG bands were readily observed and quantified  
for the rest of the groups (500 ppm and above). Marked  
induction was observed for the groups fed 750, 1000 and 1250  
ppm I3C.  
The induction of CYP1A, a marker for the Ah receptor- 
mediated mechanism, was apparent only in the highest I3C  
groups (1000 and 1250 ppm)  (Fig. 3.4).  67 
DISCUSSION 
Dietary I3C supplementation for the healthy adult human  
population has been advanced for the purpose of  
chemoprevention against estrogen-related diseases (15).  
However, after it was recognized that long-term dietary I3C  
may lead to enhancement of hepatocarcinogenesis in rats  (1)  
and trout (3,  7), and the ability of this plant derivative  
to induce both phase I and phase II enzymes involved in  
possible procarcinogen activation was documented (25, 26,  
35, 51), legitimate concerns were raised regarding possible  
risks associated with the above approach. Earlier studies  
documented tumor promotional effects of I3C at relatively  
high dietary doses (3,  7). One of the objectives of this  
experiment was to address the potency of post-initiation  
long-term I3C to act as a promoter of hepatocarcinogenesis.  
Thus, the inclusion of treatment groups with relatively low  
dietary I3C exposure (250, 500 and 750 ppm) allowed for  
determination of a possible threshold below which no  
significant promotion would be detected. Such contemplation  
would not be unreasonable since biological effects of  
dietary I3C are attributed to its acid condensation  
derivatives that are formed in the stomach upon intake (29-
32).  68 
The results are inconclusive regarding the existence of  
a threshold. The data are consistent with the hypothesis of  
no treatment effect at 250 ppm (odds ratio vs. Control = 1)  
and therefore consistent with the existence of a threshold  
in the range studied. However, the variation in the data is  
such that the results are also consistence with moderate  
treatment effects at 250 ppm based on the width of the 95%  
confidence interval (upper limit odds ratio vs. Control =  
1.46, Table 3-II) and on the observed increases in pooled  
incidences (250 ppm vs. 0 level) at the three highest doses  
of AFB1 (Table 3-1). Based on the logistic regression  
modeling, if a threshold exists at all, it would appear to  
be below 500 ppm. Further studies focusing on 250 ppm and  
lower doses of I3C would help to clarify the threshold  
question.  
Similar trend for promotion was observed with respect  
to the incidence of multiple tumors among tumor bearing  
fish.  
Post-initiation long-term dietary I3C has ambivalent  
effects depending on the animal model. It promotes  
hepatocarcinogenesis in the trout and the rat as mentioned  
above, however, it acts as an inhibitor in the C57BL/6J  
mouse (6). Possible mechanism(s) for tumor modulation could  
include Ah receptor-mediated enzyme induction (25, 34, 35)  
and/or the ability of I3C derivatives to exhibit estrogenic  69 
and/or antiestrogenic properties (29). It is known that  
estrogens promote chemically-induced carcinogenesis in rats  
(52-57) and trout (40), but inhibit in the mouse (6,  58, 59).  
It is unclear how estrogens inhibit liver tumors in mice. The  
mechanisms of estrogen-related hepatocarcinogenesis promotion  
in the rat are proposed to involve alterations in the cell  
cycle with ensuing increased cellular proliferation, and/or  
the ability of some estrogen metabolites to cause direct  
and/or indirect DNA damage resulting from reactive oxygen  
intermediates generated by redox cycling involving catechol  
metabolites of estrogens (60). The ability of I3C derivatives  
to induce P450s through the Ah receptor and also to possess  
estrogenic and/or antiestrogenic activities suggest that  
either of these mechanisms could be involved in promotion in  
the trout liver model.  
Vitellogenin is the precursor for egg yolk protein, and  
is found in all oviparous vertebrates (61). Its synthesis is  
mediated through the estrogen receptor (62) and is required  
for oocyte maturation. Thus, VG synthesis is a reliable  
estrogen biomarker in sexually immature trout. We observed  
in this experiment that, at low-I3C treatment groups, VG  
synthesis was evident whereas CYP1A was induced only in the  
1000 and 1250 ppm groups (Figure 4). Previous studies show Ah  
agonists to promote chemical hepatocarcinogenesis in trout  
(63). This may suggest that estrogenicity of I3C may play a  70 
more important role in promotion of chemically-induced hepatic  
tumors in trout, especially at lower dietary levels. In fact,  
the slope for the relative potency for promotion increases  
markedly above 750 ppm (Figure 2). This could be an  
indication of more than one mechanism being involved in the  
promotion. Perhaps, at higher I3C levels, both estrogenic  
and Ah receptor-mediated mechanisms are responsible for the  
observed promotion, but at lower dose range just the  
estrogenic pathway is active.  
When estrogenic activities of a compound of interest  
are concerned, trout is a very sensitive model for tumor  
studies. Estrogens promote liver tumors in trout. This is  
particularly relevant considering that human and trout  
estrogen receptors have equal specificity for binding  
estrogens (64).  
If I3C indeed promotes in trout by acting as an  
estrogen, its proposed supplementation for chemoprevention  
purposes should be approached with caution, until its  
mechanism(s) of promotion in trout and rats and the relation  
to human cancer risk are thoroughly understood.  71 
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Table 3-I. Summary of  liver tumor incidence in trout fed  
I3C (initiated with AFB1 as embryos by a 30 min  
immersion)  . 
I3C  (p.p.m.)  AFB1(p.p.b.)  # fish  % incidence 
0  0  200  0.0 
0  50  370  6.5 
0  100  249  9.2 
0  175  400  15.0 
0  250  400  20.5 
250  0  200  0.5  
250  50  387  4.4  
250  100  259  11.6  
250  175  400  18.8  
250  250  400  25.3  
500  0  200  0.0  
500  50  374  5.1  
500  100  285  9.5  
500  175  400  23.8  
500  250  400  27.5  
750  0  200  0.0  
750  50  286  9.8  
750  100  189  17.5  
750  175  300  28.3  
750  250  300  32.3  
1000  0  200  0.0  
1000  25  300  9.7  
1000  50  270  18.9  
1000  100  180  23.9  
1000  175  300  46.0  
1250  0  200  0.5  
1250  25  300  17.0  
1250  50  270  33.0  
1250  100  164  53.1  
1250  175  300  78.0  73 
Table 3-II.Odds ratio and probability values for promotion  
of tumor incidence and multiplicity'  
I3C  Tumor incidence  p-value  Multiple tumors'  p-value  
(ppm)  Odds ratio  Odds ratio  
vs. control2  vs. control  
(95% CI3)  (95% CI)  
250  1.15 (0.91,  1.46)  0.24  1.43 (0.82,  2.55)  0.22  
500  1.30 (1.03,  1.65)  0.027  1.50 (0.87,  2.63)  0.15  
750  2.00 (1.57,  2.54)  <0.0001  1.92 (1.13,  3.36)  0.019  
1000  4.34 (3.37,  5.60)  <0.0001  3.92 (2.32,  6.820  <0.0001  
1250  13.6 (10.6,  17.6)  <0.0001  8.24 (5.06,  13.9)  <0.0001  
'The group containing fish fed 1250 ppm I3C is not included since it was  
omitted from the model involving forced parallelism for exhibiting  
somewhat higher levels of promotion.  
2lnitiated controls.  
3Confidence interval.  
'Incidence of multiple tumors among tumor bearing fish.  74 
Table 3-111. Histological classification of liver  
tumors in trout fed I3C, initiated as  
embryos with AFB1 by a 30 min immersion.  
% of total tumors by tumor type'  
I3C  HCC  MC  CCC  HCA  MA  CCA  
(ppm)  
0  45.8  38.5  1.9  7.7  0.0  6.1  
250  38.3  41.7  2.1  12.0  0.9  5.0  
500  51.3  28.3  1.6  12.1  0.2  6.5  
750  66.1  19.1  0.4  9.8  0.8  3.8  
1000  68.5  22.4  1.2  6.1  0.0  1.8  
1250  68.7  26.4  0.1  4.3  0.0  0.5  
overall average  56.45  29.4  1.2  8.7  0.3  3.95  
a HCC, hepatocellular carcinoma; MC, mixed carcinoma; CCC,  
cholangiocellular carcinoma; HCA, hepatocellular adenoma;  
MA, mixed adenoma; CCA, cholangiocellular adenoma.  Promotion of AFB1-Carcinogenesis by 13C
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Figure 3.1. Promotion of AFB1- induced hepatocarcinogenesis by dietary  indole-3-carbinol. Tumor  
incidence data were obtained by logistic regression with enforced parallelism and  
with the inclusion of sampling time point in the model. Promotion  was significant  
starting from the 500 ppm group. For 250 ppm, pomotion was significant only for the  
higher dose AFB1- initiated groups.  6 
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Figure 3.3. Induction of plasma vitellogenin  (estrogen biomarker) in trout   from the tumor study, 
fed I3C continuously at 0, 250, 500,  750, 1000, 1250 ppm. Stro  ng induction of 
vitellogenin is apparent at most dietary levels whereas CYP1A   was induced only at 
highest I3C groups (Fig 3.4) suggesting a more important role   for estrogenic 
properties of I3C in promotion at low dietary levels.  Figure 3.4	  Induction of hepatic microsomal CYP1A in trout from the tumor study, fed I3C  
continuously at 0, 250, 500, 750, 1000, 1250 ppm. Induction is apparent only  
at highest dietary I3C levels.  79 
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Chapter 4  
INDUCTION OF CYP1A BY INDOLE-3-CARBINOL, ITS ACID  
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FROM TROUT, MOUSE AND RAT  
A. Oganesian, J.M. Spitsbergen, and D.E. Williams  
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ABSTRACT  
I3C is found at relatively high levels in  
cruciferous vegetables and has been shown to act as a  
dual modulator of carcinogenesis, depending on species,  
target organ and conditions of the experiment. It is  
believed that I3C condensation products are responsible  
for the in vivo effects of I3C administration. One of the  
candidate mechanisms for tumor promotion by I3C is  
proposed to be mediation through the aryl hydrocarbon  
(Ah) receptor. In this study we utilized precision-cut  
liver slices from rainbow trout (Oncorhynchus mykiss),  
F344 rats and C57B1/6J mice to analyze various  
xenobiotics, including I3C and derivatives, for their  
potency to induce CYP1A1. Slices were incubated for 48 h  
in Waymouth medium at 34°C(rat, mouse) or 14°C (trout)  
and viability monitored histologically and by measuring  
ATP levels. CYP 1A1 protein levels were measured by  
western blotting. In all three species, ICZ was the most  
potent inducer among I3C related products (EC50 2 11M for  
trout, 12 4M for rat and 15 4M for mouse slices). When  
incubated in optimum conditions using the well plate- 
shaker system, rat, mouse and trout liver slices can be  
kept viable for at least 48 h and CYP1A1 (1A in trout)  89 
can be induced to levels comparable to those seen  in  
microsomes isolated from animals induced in vivo.  
Abbreviations: Ah, aryl hydrocarbon; I3C, indole-3-carbinol;  
133', 3,3'-diindolylmethane; LT, linear trimer, [2-(indo1-3-
ylmethyl)-indol-3-yl]indo1-3-ylmethane); CT, cyclic trimer  
(5,6,11,12,17,18-hexahydrocyclonona[1,2-b:4,5-b':7,8-
b"]triindole); ICZ, indolo[3,2-b]carbazole; ANF, a-
naphthoflavone; BNF, P-naphthoflavone; HCB,  
hexachlorobiphenyl; TCDD, 2,3,7,8-tetrachlorodibenzo-p-
dioxin.  90 
INTRODUCTION  
During recent years the utilization of high precision  
tissue slices has been increasingly employed for in vitro  
metabolism studies (1-3). Tissue slices, to a large degree,  
maintain the structural integrity of the tissue and thus  
provide an advantage over cultured cells.  
Our laboratory is investigating the mechanism(s) of  
hepatocarcinogenesis promotion by a plant secondary  
metabolite, indole-3-carbinol (I3C) which is found at  
relatively high levels in cruciferous vegetables. It is  
believed that I3C condensation products are responsible for  
the in vivo effects of I3C administration (4-8). Dietary I3C  
administration is reported to modulate carcinogenesis and  
one of its proposed mechanisms of action is via the Ah  
receptor pathway. This pathway is believed to be the  
mechanism of TCDD-induced toxicity and tumor promotion (TCDD  
possesses the highest affinity for binding to the Ah  
receptor of all known ligands)  (9-12). The Ah receptor is a  
cytosolic protein with a basic helix loop helix structure  
similar to other transcription factors (10), which binds  
various xenobiotics of planar stereostructure in a step  
involving dissociation from two HSP90 subunits. The ligand-
bound receptor thdreafter translocates into the nucleus and  
dimerizes with the Ah receptor nuclear translocator protein  91 
(ARNT)  (12). The dimer acts as a transcription factor by  
playing a role in the activation of a cascade of genes  
downstream from the xenobiotic-response elements (XRE) in  
the nucleus. These genes include several phase I and II  
enzymes involved in xenobiotic metabolism. Induction of  
enzymes of the CYP1A subfamily (particularly, CYP1A1) is  
considered a marker for an affinity for binding to the Ah  
receptor (12).  
The most common approach for incubation of tissue  
slices is the so-called dynamic culture system (13). One of  
the drawbacks of this system concerns the question of  
availability of test compounds to the cells in slices, since  
contact with incubation medium is limited. In the well-
plate-shaker system (3), slices are submerged into medium at  
all times and availability of the substrate is not limiting.  
We here demonstrate that, when incubated in proper  
conditions using the well-plate shaker system, rat, mouse  
and trout liver slices can be kept viable for at least 48 h  
(longer for trout) and CYP1A1 (1A in trout) could be induced  
at levels comparable to those seen in vivo.-92 
MATERIALS AND METHODS  
Materials  
I3C was purchased from Aldrich Chem. (Milwaukee, WI);  
BNF, ANF, incubation media and supplies from Sigma Chem. Co.  
(St. Louis, MO) unless otherwise noted; 3,4,5,3'4'5'- and  
2,4,5,2'4'5'-hexachlorobiphenyl from AccuStandard (New Haven,  
CT); ICZ was generously provided by Dr. Leonard Bjeldanes of  
the University of California at Berkley, and 12-well plates  
from Fisher Scientific (Santa Clara, CA). Rabbit polyclonal  
antibody against trout CYP1A was generously provided by Dr.  
Donald Buhler of Oregon State University. Rabbit-anti rat  
CYP1A1 antibody was purchased from Oxygene (Dallas, TX).  
Animals  
Sexually immature rainbow trout (approximately 1 year  
old) from Oregon State University Food and Nutrition  
Laboratory were used. Five-six week-old male C57BL/6J mice  
were purchased from Jackson Laboratories (Bar Harbor, MA) .  Six  
week-old Fisher 344 rats were purchased from Simonsens  
(Gilroy, CA).  
Incubation conditions  
All operations with liver slices were performed at  
maximum sterile conditions at ice-cold temperature until the  
start of incubation. The microtome compartment of the  
Krumdieck Tissue Slicer (Alabama R&D, Munford, AL) was  93 
sterilized according to manufacturer's instructions the day  
prior to preparation of slices. For trout liver slices, the  
Hanks modified salts buffer was supplemented with 10 mM HEPES,  
8 mM sodium bicarbonate, 50 mg/ml gentamicin and 1% BSA, pH  
7.4. Rat and mouse liver slices were incubated in the Waymouth  
MB 752/1 medium, supplemented with 10 mM HEPES,  8 mM sodium  
bicarbonate, 50 mg/ml gentamicin and 10% fetal calf serum.  
Media was filter-sterilized using a Gelman Vacucap filter  
(Fisher) into sterile containers and stored at 4°C. The same  
media was used for transportation of livers, slice preparation  
and incubation. After animals were sacrificed, livers were  
collected into ice-cold medium, and slices (250 mm in  
thickness) prepared from liver tissue cores (8 mm in diameter,  
prepared with a tissue coring press (Alabama R&D)). Slices  
were then randomized and distributed into 12-well plates (1  
slice per 1 ml of medium per well). Test compounds were added  
into medium prior to the start of incubation. At 24 h, slices  
were transferred into new plates with fresh medium. Incubation  
of slices was conducted at 14°C for trout, and 34°C for rat  
and mouse slices. The plates were held in tight-seal  
containers which were gassed with 95% 02/5% CO2 repeatedly  
several times a day. Containers were kept inside an incubator  
on an orbital shaker set at 110 rpm. Table 4-I lists all  
compounds tested and ranges of concentrations used for  
incubation(s).  94 
Viability  
ATP levels were measured in slice homogenates at 0, 24,  
and 48 h using a method based on spectrophotometric  
determination of ATP-dependent NADH consumption in an enzyme- 
linked conversion of 3-phosphoglycerate to 1,3-
diphosphoglycerate (Sigma ATP assay kit).  
At 0,  12, 24 and 48 h, several slices were fixed in buffered  
formalin and later evaluated histologically for cell  
viability. The percentage of viable cells in good histological  
condition was estimated in randomly chosen sections of slices.  
Preparation of slice homogenates  
Liver slices were homogenized in 4-5 volumes of ice  
cold 0.1 M potassium phosphate buffer (pH 7.4) containing  
0.15 M KC1,  1 mM EDTA,  1 mM phenylmethylsulfonyl fluoride,  
and 20% glycerol. Homogenates were subjected to a 5,000 g  
centrifugation for 5 min to remove debris. The resulting  
supernatant was stored at -80°C until analysis. Protein  
determinations were made according to the method of Lowry et  
al.(14).  
Electrophoresis and immunoblotting  
CYP1A levels were examined in slice homogenates.  
Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE)  (15) on 8 %  
acrylamide and electrophoretically transferred onto  
nitrocellulose (Bio-Rad Trans-Blot). Blots were probed with  95 
rabbit polyclonal antibodies to trout CYP1A, followed by a  
horseradish peroxidase-linked secondary antibody. Proteins  
were detected using an Amersham ECL chemiluminescence kit  
(Amersham Corp., Arlington Heights, IL). Western blots were  
scanned on a flatbed HP Scanjet IIcx scanner. Densitometry was  
performed with the public domain software NIH Image, version  
1.57 (written by Wayne Rasband at the US National Institutes  
of Health).  
Statistical analysis  
Differences between groups were tested using one-way  
analysis of variance, followed by the least significant  
difference multiple comparison test using the statistical  
software package, Statgraphics (version 5.0),  (Statistical  
Graphics Corporation, Princeton, New Jersey). A probability  
value of less than 0.05 was considered significant. EC50  
values were calculated by linear interpolation using  
densitometry data from western blots. Triplicates were used,  
each replicate representing a pool of 4 slices.  96 
RESULTS  
The viability of slices was assessed histologically, as  
well as by analyzing ATP levels in slice homogenates. Fig.  
4.1 shows changes in ATP levels over time throughout the  
incubation. Trout slices were the least affected after 48 h  
of incubation (approximately 80 % of ATP were recovered,  
versus 70-75 % for rat or mouse slices, compared to levels  
seen in fresh slices (0 h)). Figs. 4.2a, 4.2b and 4.2c are  
photographs of representative histological sections taken  
from trout, rat and mouse liver slices. The estimates of  
living cells were consistent with ATP observations.  
Table 4-11 contains EC50 values for CYP1A1 (CYP1A for  
trout) induction in trout, rat and mouse liver slices. CYP1A  
induction by all compounds tested was observed only for  
trout liver slices. EC50 values were not calculated for  
compounds that induced at only one or two concentrations  
(e.g. LT and CT induced only at highest concentration tested  
(500 gM)).  
Fig. 4.3 represents a western blot of CYP1A induction  
by some of the compounds incubated with trout liver slices.  
ICZ exhibited the greatest potency among the I3C derivatives  
(EC50=2gM), and 3,4,5,3'4'5'-HCB and BNF were the most  
efficacious inducers in trout slices.  97 
Fig. 4.4 represents CYP1A1 induction in rat liver  
slices. ICZ again was the most potent among I3C derivatives.  
ANF was an effective inducer at relatively high levels as  
well. The greatest efficacy for induction was observed, by  
BNF, however, ICZ was a more potent inducer (EC50=12  
versus 38 4M for BNF). CYP1A induction in mouse liver slices  
was reduced compared to trout or rat, although the potency  
for the strongest inducers were comparable to the rat (EC50,  
ICZ=15 4M; BNF=34 gM).  
Representative western blots are shown in Fig. 4.5,  
documenting CYP1A1 (1A in trout) induction (dose-response).  
Fig. 4.6(a, b) shows a dose-response for CYP1A1  
induction by 2,4,5,2'4'5'-HCB in trout and mouse liver  
slices (no induction was observed in rat slices).  98 
DISCUSSION  
Tissue slices are a convenient tool for studying  
xenobiotic metabolism and enzyme induction. Although total  
P-450 levels decrease in the course of incubation of slices,  
they can still be used for studying the induction of  
individual CYP isoforms (1,  13).  
Ah receptor-mediated induction of P450s is one of the  
mechanism(s) responsible for toxic events including tumor  
promotion associated with exposure to certain xenobiotics  
including dioxins, dibenzofurans, polyhalogenated biphenyls  
and polycyclic aromatic hydrocarbons (PAHs)  (11, 12). In  
particular, CYP1A1 is believed to be responsible for  
metabolic activation of procarcinogens of PAH group. These  
enzymes are also involved in detoxifying pathways for  
elimination of xenobiotics.  
Dietary I3C has been shown to act as a modulator of  
carcinogenesis in various animal models (16-24). Depending  
on species, target organ, timing and dose of administration,  
I3C may either inhibit tumorigenesis (mammary tissue in  
rodents, mouse liver) or promote (trout, rat liver (long-
term exposure), mouse liver (short-term exposure). Although,  
transient induction of enzymes of the CYP1A subfamily is  
implicated in the mechanism(s) of protection against some  
dietary carcinogens, their persistent expression is one of  99 
the characteristics of toxicity seen in association with  
exposure to some environmental xenobiotics, including TCDD,  
and PCBs (11,  12) .  
Dietary I3C yields various acid condensation products  
(formed in the stomach) that have been shown to possess  
affinity for binding to the Ah receptor (4-8). This study  
utilized the liver slices approach to address the issue of  
efficacy and potency of various I3C derivatives for  
induction of CYP1A1 (1A in trout) in vitro in comparison  
with common Ah ligands. The scarce availability and the  
tendency to undergo physico-chemical breakdown renders in  
vivo studies with some of the I3C derivatives very  
difficult. The tissue slice technique allows conducting  
experiments with very small amounts of these compounds. One  
of the drawbacks of this approach, however, is the  
difficulties associated with the aqueous solubility of some  
test compounds at relatively high concentrations.  
As expected, the planar HCB isomer (3,4,5,3'4'5'-HCB)  
and BNF (a proposed strong Ah agonist) induced CYP1A1 (1A in  
trout) with the greatest efficacy in all models. An  
interesting observation was made with the non-planar HCB  
(2,4,5,2'4'5'-HCB) which induced CYP1A1 in mouse and trout  
slices, but not in the rat, and induction was evident only  
at low concentrations (Fig. 4.6).  100 
It has been shown that, among all I3C derivatives, ICZ  
has the highest affinity for binding to the Ah receptor and  
has been characterized as a TCDD-mimic (7). As we  
demonstrate here, ICZ indeed induces CYP1A1 (1A for trout)  
in liver slices very strongly and at relatively low  
concentrations in all three animal models studied. However,  
being only one of the minor derivatives of I3C acid  
condensation, ICZ's relative role in the mechanism(s) of  
events resulting from dietary I3C in vivo is not entirely  
clear. If ICZ is formed in very minute amounts in vivo upon  
dietary I3C exposure, it is possible that other mechanism(s)  
of action of I3C derivatives, including documented  
antiestrogenicity and/or estrogenicity, could be responsible  
for carcinogenesis modulation in the trout, rat, or mouse.  101 
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Table 4-I. Compounds and incubation concentrations.  
Compound  comment  concentration range  
(JIM )  
I3C  0.1-2000  
133'  (dimer of I3C)  0.01-200  
LT  (linear trimer)  0.01-500  
CT  (cyclic trimer)  0.01-500  
ICZ  (indolocarbazole)  0.001-200  
ANF  0.01-200  
BNF  0.01-80  
3,4,5,3'4'5'-HCB  0.01-200  
2,4,5,2'4'5'-HCB  0.01-200  103 
Table 4-11 EC501 values calculated for CYP1Al2  
induction by compounds tested (gm)  
compound  trout  rat  mouse  
13C  87  
133'  6  50  
LT  
CT  
ICZ  2 12 15  
ANF  37  77  
BNF  3 38 34  
3-HCB3  1  10  22  
2-HCB4  65  4  
1 blanks indicate induction was either not  
detectable or was observed at less than three  
concentrations tested.  
2 CYP1A for trout  
3 3,4,5,3'4'5'-HCB  
4 2,4,5,2'4'5'-HCB  0 
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Figure 4.1. Viability of liver slices over the course of 48 h incubation period.  
Measurement of ATP levels in slice homogenates.  105 
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Figure 4.2. Viability of liver slices over the course of 48  
h incubation period: Histological  observations:  
(a) trout;  (b)  rat;  (c) mouse. After 48 h,  
estimated 80% of cells in trout slices  and 70-
75% of cells in rat and mouse slices appear  
viable.  (a)  Trout.  105b  
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Figure 4.2  (b). Viability of liver slices over the course of  
48 h incubation period: Histological  
observations: Rat.  105c  
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Figure 4.2 (c). Viability of liver slices over the course of  
48 h incubation period: Histological  
observations: mouse.  stds  45  
Figure 4.3. Western blot of CYPLA induction by compounds incubated with trout liver  
slices. Left to right: 1-3, purified trout CYP1A (0.1-0.5 pmol); 4, control;  
5, ANF; 6, BNF; 7,  I3C;  8,  133'; 9,  ICZ; 10, 2,4,5,2'4'5'-HCB; 11,  
3,4,5,3'4'5'-HCB. All compounds are shown at their highest inducing  
concentration. Protein amount loaded: 20 'lg.  EC50 values were calculated from  
dose-response curves by linear interpolation.  1 3  8 
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Figure 4.4. Western blot of CYP1A1 induction by compounds incubated with  rat liver slices.  
Left to right: 1-3, in vivo BNF-induced rat microsomes; 4, BNF; 5, ANF; 6,  
I3C; 7, control; 8,  ICZ; 9, LT; 10, CT; 11, 133'. All compounds are shown at  
their highest inducing concentration. Protein amount loaded: 20 lig. EC50  
values were calculated from dose-response curves by linear interpolation.  108 
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Figure 4.5. Representative western blots of dose-response  
for CYP1A1 induction in precision-cut liver slices.  
First well (left) contains BNF-induced (in vivo)  
microsomes. Protein load: 20 lig. Increasing  
concentrations (Table 4 -I) from left to right.  109 
AINEMIllak  10 Op IV% AIM% 
2,4,5,2'4'5'-HCB in mouse liver slices  
0  0.0I  
wm.  IIMP 
0 2000N 
2,4,5,2'4'5'-HCB in trout liver slices  
Figure 4.6. Induction of CYP1A1 (1A in trout)  by non- planar  
2,4,5,2'4'5-hexachlorobiphenyl in mouse and trout liver  
slices: dose-response. Protein load: 20 mg. In both mouse  
and trout, induction was observed at lower concentrations,  
fading (trout) at higher concentrations.  110 
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Chapter 5  
LONG TERM DIETARY INDOLE-3-CARBINOL INHIBITS  
DIETHYLNITROSAMINE-INITIATED HERATOCARCINOGENESIS IN  
THE INFANT MOUSE MODEL  
A. Oganesian, J.D. Hendricks, and D.E. Williams  
Toxicology Program, Department of Food Science, and the  
Marine/Freshwater Biomedical Sciences Center, Oregon State  
University, Corvallis, OR.  114 
ABSTRACT  
Indole-3-carbinol (I3C), a natural component from  
cruciferous vegetables, has been demonstrated to be a  
modulator of carcinogenesis in various animal models. Along  
with the promise of I3C as a possible chemopreventive agent  
for human breast cancer, some concerns have been raised  
regarding the tumor- promotional potency of this compound in  
other target organs. In this study we examined the hepatic  
tumor-modulatory properties  of I3C fed to C57BL/6J mice,  
initiated with diethylnitrosamine (DEN). Infant male mice were  
initiated with 0,  2 or 5 mg/kg DEN (ip injection) at 15 days  
of age. Mice were weaned nine days later and immediately put  
on AIN76A semipurified diet (with no antioxidants)  containing  
0 or 0.15 %  (1500 ppm) I3C. In addition, at the age of two  
months, one group of mice initiated with 2 mg/kg DEN was  
injected ip with a single dose (20 mg/kg) of 3,4,5,3'4'5'-
hexachlorobiphenyl (HCB) to serve as a positive control group  
for promotion. Mice were sampled for hepatic tumors at the age  
of six or eight months. Each sampled group contained 11-12  
mice except the HCB group (9 animals). After 8 months, there  
was a statistically significant (p<0.0005)  inhibition of  
hepatocarcinogenesis observed for I3C-fed animals initiated  
with the high dose of DEN. A single injection of HCB at two  
months of age significantly (p=0.0003) enhanced  115 
hepatocarcinogenesis in mice initiated with 2 mg/kg DEN. There  
was no statistically significant difference between groups  
sampled at six months of age. Our observations indicate that  
long term administration of I3C in the diet inhibits DEN- 
initiated  hepatocarcinogenesis in the infant mouse model.  
Keywords:  
Ah, aryl hydrocarbon; DEN, diethylnitrosamine; I3C,  
indole-3-carbinol; HCB, 3,4,5,3'4'5'-hexachlorobiphenyl.  116.  
INTRODUCTION  
Indole-3-carbinol (I3C) is a hydrolysis product of  
glucobrassicin, found in cruciferous vegetables such as  
broccoli, cabbage, and Brussels sprouts. Dietary  
administration of I3C has been associated with chemoprevention  
of cancers [1-4] of the endometrium [5], lung [6-9], mammary  
tissue [10], tongue [11], colon [12] and liver [4,13] in  
various animal models and is proposed as a chemoprevention  
agent for use against breast and ovarian cancers in humans  
[14]. Several possible mechanisms for inhibition of  
carcinogenesis by I3C have been proposed, one being the  
alteration of estrogen metabolism [15-20]. In addition, I3C  
has been reported to inhibit glutathione-S-transferase-
mediated steroid binding activity [21], scavenge free radicals  
[22], modulate the activity of multidrug resistance [23], and  
alter the expression of various phase I and phase II drug- 
metabolizing enzymes [24-28] contributing to detoxification of  
carcinogenic compounds. Upon dietary administration, I3C  
undergoes condensation reactions in the acidic environment of  
the stomach. Evidence obtained to date documents that these  
condensation products, and not I3C itself, are responsible for  
its biological effects [29-32]. Certain I3C condensation  
products exhibit relatively high affinity for binding to the  
Ah receptor [33-36] as well as antiestrogenic and weak  117 
estrogenic activities [29]. Another condensation product, the  
dimer 3,3'diindolylmethane (I33'), is a major component of the  
I3C acid condensation mix formed in vitro or in vivo [37].  
133' is capable of inducing apoptosis in human cancer cells  
[38] and is an effective inhibitor in vitro of cytochromes  
P450 [39,40].  
In most carcinogenesis models I3C acts as a  
chemopreventive agent when administered concurrently with the  
carcinogen or prior to initiation. However, a few studies have  
reported that, when given after initiation (promotion-
progression stage), I3C acts as an enhancer of carcinogenesis  
[1,  3, 13]. One report concludes that I3C may be mutagenic  
when administered in diet along with nitrites [41].  
In this study we examined the hepatic tumor modulatory  
potency of I3C in the male C57BL/6J mouse, initiated with DEN.  
Synthetic estrogens are reported to have liver tumor promoting  
activities in rats [42,43], however, mice apparently are not  
susceptible to estrogen-mediated promotion of hepatic  
carcinogenesis [44]. We investigated whether promotion by I3C  
is evident in mouse as it is in rat (1) and trout [45]. If I3C  
enhances tumorigenesis through estrogenic mechanisms, mice may  
be resistant to these effects.  118 
MATERIALS AND METHODS  
Chemicals  
Diethylnitrosamine (DEN) was purchased from Sigma  
Chemical Co.  (St. Louis, MO) and indole-3-carbinol  from  
Aldrich Chemical (Milwaukee, WI).  
Animals  
All experimental procedures were conducted under NIH  
guidelines for the care and use of laboratory animals.  
C57BL/6J mice were purchased from Jackson Laboratory (Bar  
Harbor, ME) as litters, each containing 5 males.  
Animal Treatments and Diets  
At 15 days of age mice were injected ip with 2 or 5  
mg/kg DEN in saline. DEN stock concentrations were prepared  
such that for each g of body weight mice received 10 µl stock  
solution or saline for controls. The average body weight at  
day 15 was 5 g. Small gauge insulin syringes were used for  
injection procedures. Nine days after injection mice were  
weaned and experimental diets started immediately. AIN76A  
semipurified rat/mouse diet containing no antioxidants  
(butylated hydroxyanisole or butylated hydroxytoluene) was  
prepared using components from ICN (Costa Mesa, CA). I3C was  
added into the diet in dry powdered form. Once in mixtures,  119 
I3C is known to undergo spontaneous breakdown. For this reason  
the stability of I3C in the AIN76A powdered diet was monitored  
by solubilizing fractions of the diet and recovering I3C and  
condensation products using HPLC with a UV-detector. After 7  
days at least 80 % of I3C was still in the parent form. I3C  
diets were prepared every week and stored at 4°C until used.  
Animals were divided into ten treatment groups (Table  
I). Groups 1 and 2 received ip 2 mg/kg DEN and control diet;  
groups 3 and 4 received ip 5 mg/kg DEN and control diet;  
groups 5 and 6 received 2 mg/kg ip DEN and 1500 ppm I3C  in  
diet; groups 7 and 8 received 5 mg/kg ip DEN and 1500 ppm I3C  
in diet; group 9 received ip saline and 20 mg/kg single ip  
injection of 3,4,5,3'4'5'-hexachlorobiphenyl (HCB) at the age  
of two months, and received control diet; group 10 received ip  
2 mg/kg DEN, 20 mg/kg HCB at two months and control diet.  
Groups 1-3, 5, and 9 consisted of 11 mice, groups 4,  6-8  12  
mice, and group 10 had 9 animals. Groups 1,  3,  5, and 7 were  
sampled for liver tumors at six months of age; groups 2,  4,  6,  
8-10  at eight months. Mice were euthanized in a CO2 chamber  
according to the 1993 AVMA panel on Euthanasia [46].  
In a previous experiment, saline-injected C57BL/6J male  
mice fed control AIN76A diet (negative control group) showed  
no tumors and our decision not to include a negative control  
group in the second study was based on this observation.  120 
Animal Husbandry  
Animals were kept at the Oregon State University  
Laboratory Animal Resources Center. Lactating females with  
litters were housed in plastic cages with polyurethane covers.  
Pups remained with the mother until weaning (day 24). Once  
weaned, mice were housed one per cage, diet given daily, and  
water and bedding changed twice a week. Diet and water were  
available ad libitum. Clinical observations and body weights  
for individual mice were recorded weekly.  
Necropsy  
At the age of six (groups 1,  3,  5, and 7) or eight (the  
rest of the groups) months, mice were weighed and euthanized  
by CO2 asphyxiation. Blood was collected by cardiac puncture,  
allowed to stand for 1-3 h and then centrifuged to obtain  
serum. Livers were removed, weighed and examined  
macroscopically for tumors. Tumors  0.5 mm in diameter were  
counted. All livers were fixed in Bouins fixative for  
processing to paraffin sections and microscopic examination. A  
tumor-free section from each liver was frozen in liquid  
nitrogen immediately after examination.  
Statistics  
All data (unless otherwise noted) are presented as mean  
± SD. Data for treatment groups of interest were compared by  121 
an unpaired, two-tailed t-test for tumor multiplicity and size  
data, and Fisher's two-tailed exact test for incidence data.  
All observations with p < 0.05 were considered significantly  
different.  122 
RESULTS  
Body Weight  
Fig. 5.1 shows the body weight gain throughout the  
study. Body weights were recorded weekly and were not  
significantly affected negatively by consumption of 1500 ppm  
I3C in diet. Our visual observations showed that groups fed  
I3C diet consumed the same amount of food as groups fed  
control diet. A slowdown of growth was observed for groups 9  
and 10 after injection of HCB at two months of age. This trend  
persisted for both groups throughout the rest of the  
experiment. By week 33, the average weight for mice from  
groups 9 and 10 were 33 and 35 g, respectively, versus 37-41 g  
for mice from the rest of the groups.  
Liver weight  
There was a significant increase (p < 0.05) in the liver  
somatic index (compared to the rest of groups) for both HCB- 
treated groups, 7.34 % for group 9 (saline-injected, 20 mg/kg  
HCB-injected at two months, control diet) and 6.68 %  (p <  
0.05) for group 10 (2 mg/kg DEN,  20 mg/kg HCB)  (Table 5 -I).  
Hepatic Neoplastic Findings  
Pale white neoplasms where found macroscopically in the  
livers of initiated mice (all but group 9). Table 5-I shows  
the differences between treatment groups with respect to tumor  
incidence, multiplicity and size. The tumor multiplicity is  123 
also depicted in Figs. 5.2 and 5.3 to illustrate the data for  
each individual mouse. A 100 % tumor incidence was observed in  
all groups, except groups 1  (8/11, 2 mg/kg DEN, control diet,  
sampled at 6 mo.), 6 (9/12, 2 mg/kg DEN, 1500 ppm I3C diet,  
sampled at 8 mo.), and 9 (uninitiated)., The difference in  
tumor incidence between these and corresponding treatment  
groups was not statistically significant (p > 0.2). However, a  
significant inhibition of tumor multiplicity was observed  
between groups 8  (12.5 ± 11.9, 5 mg/kg DEN, 1500 ppm I3C diet,  
sampled at 8 mo.) and 4  (35.4 ± 15.1, 5 mg/kg DEN, control  
diet, sampled at 8 mo.), Fig. 5.3. The difference in tumor  
size between these groups (0.7 ± 0.2 and 1.1 ± 0.2 for 8 and  
4, respectively) was statistically significant as well (p <  
0.0003)  .  
Histologically, hepatocytes of most DEN-treated mice  
displayed extensive lipidosis, especially in the portal zones.  
The neoplasms were consistently the same from group to group,  
and were classified as basophilic, well-differentiated, non-
invasive hepatocellular adenomas. Lipid vacuoles were also  
frequently observed in the neoplastic hepatocytes.  
Other observations  
Group 9 (non-initiated, HCB-treated, control diet) was  
the only group with zero tumor incidence. Four  animals (from  
eleven) from this group had a scruffy skin condition during  124 
the last 2-3 weeks of the study and were treated with  
tetracycline in the drinking water, by the attending DVM (Dr.  
Nephi Patton). Two of those four mice had a moderately  
enlarged spleen. One mouse had a 3 mm cyst on the kidney.  125 
DISCUSSION 
A major objective of this study was to test whether long  
term post-initiation exposure to dietary I3C promotes  
hepatocarcinogenesis in mice as it does in rats (Stresser, et  
al., unpublished data; [1]), and trout [3, 13].  
The C57BL/6J mouse was selected because congenic animals  
from this strain (C57BL/6J(Ahd/d), possessing a defective aryl  
hydrocarbon (Ah) receptor gene, are available and could be  
used to demonstrate whether promotion is linked to Ah  
receptor-mediated mechanisms. On the other hand, if modulation  
of hepatocarcinogenesis by I3C is mediated through estrogenic  
mechanisms, inhibition rather than promotion could be expected  
as it is reported that estrogens normally suppress liver tumor  
development in mice [44]. An inhibition of DEN-induced  
hepatocarcinogenesis by ovarian hormones has been reported for  
the C57BL/6J strain [47]. Several strains of male mice, when  
treated with 10 ppm ethinyl estradiol, exhibited reductions in  
the number and size of altered hepatic foci in a two-stage  
carcinogenesis model [49]. However, it is well established  
that rats are susceptible to promotion of liver tumors by  
synthetic estrogens [42, 43, 49]. The tumor modulating effects  
of I3C may be attributed to estrogenic and antiestrogenic  
activities of acid condensation products.  126 
In this study, mice initiated with 5 mg/kg DEN as  
infants and sampled at eight months of age, exhibited  
statistically significant inhibition of hepatocarcinogenesis  
when fed 1500 ppm I3C from weaning throughout the duration of  
the experiment (Fig. 5.2, Table 5 -I). The 13C-dependent  
protection was apparent. both at the level of tumor  
multiplicity and size. For the mice sampled at six months, a  
single outlier in group 7  (5 mg/kg DEN, 1500 ppm I3C diet,  
average number of tumors was 9.7) with 53 tumors prevented  the  
demonstration of significant tumor reduction. With the  
exclusion of this mouse, the difference between this group and  
the corresponding control would be significant, as well. No  
statistically significant differences were observed between  
control and I3C diet groups for mice initiated with low-dose  
DEN (2 mg/kg) at either six or eight months.  
Our finding that 1500 ppm dietary I3C inhibits DEN- 
initiated hepatocarcinogenesis in C57BL/6J mouse supports the  
speculation that I3C and its acid condensation derivatives may  
mediate chemically induced carcinogenesis through estrogen- 
dependent pathways. The success of the use of dietary I3C  
supplementation for preventing estrogen-related diseases  
without increasing the risk of promotion of  
hepatocarcinogenesis in humans may depend on whether the  
mechanism(s) of action of I3C derivatives in humans is more  
like the mouse or the rat and trout.  127 
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Group  DEN  Promotion  Diet  Necropsy  Final  Liver wt  Tumor  Macroscopic  Mean size 
(mg/kg)  treatment  age  body wt  (% of body wt)  incidence  hepatic  (mm) 
(HCB, mg/kg)  (months)  (g)  neoplasms 
(no.  0.5 mm) 
1  2  control  6  37.9 ±1.9  5.01 ±0.50  8/11  3.4 ± 1.3  0.7 ± 0.3 
2  2  control  8  38.5 ±5.1  5.48 ±0.91  11/11  4.2 ± 2.4  1.1 ± 0.5 
3  5  control  6  37.1 ±4.3  5.01 ±1.05  11/11  16.1 ± 7.0  0.8 ± 0.1 
4  5  control  8  40.8 ±2.4  5.73 ±1.18  12/12  35.4 ± 15.1  1.1 ± 0.2 
5  2  13C1  6  41.0 ±3.4  5.54 ±1.34  11/11  2.8 ± 2.6  0.8 ± 0.4 
6  2  13C  8  38.4 ±3.8  5.81 ±1.15  9/12  6.9 ± 6.2  0.9 ± 0.3 
7  5  I3C  6  36.8 ±4.1  5.51 ±1.20  12/12  9.7 ± 14.3b  0.8 ± 0.4 
8  5  I3C  8  37.7±2.3  5.17 ±0.66  12/12  12.5 ± 11.9  0.7 ± 0.2 
9  0  20  control  8  32.4 ±6.7a  7.34 ± 1.6a  0/11  -
10  2  20  control  8  35.2 ±6.6a  6.68 ± 1.0a  9/9  18.3 ± 10.3a  1.2 ± 0.3 
Male C57BL/6J mice received i.p. injections of DEN (2 or 5 mg/kg) or saline at 15 days of age. Nine days after injection mice were weaned and fed 
AIN76A semipurified diet (no BHA or BHT) containing 0 or 1500 ppm I3C. Groups 9 and 10 received ip injection of 20 mg/kg HCB attwo months of 
age. Values are mean ± SD of 11-12 mice (9 mice for group 10). 
a - significantly different from corresponding control group  
b  - significantly different from corresponding control (group 3) with the exclusion of one outlier (see text)  
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Figure 5.1. Body weight records of mice from the tumor study. Mice were treated on day 15 with 0,  2,  
or 5 mg/kg DEN and fed control or I3C diet (1500 ppm). Two groups were also injected  
ip with a single dose (20 mg/kg) of 3,4,5,3'4'5'-HCB at two months of age. Mice were 
sampled at six or eight months.  (A) Weight records up to six months;  (B) weight 
records from sixth to eighth months.  Tumor multiplicity in mice at 6 months  
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Figure 5.2. Tumor multiplicity data for groups sampled for tumors macroscopically at six  
months.  Tumor multiplicity in mice sampled at 8 months 
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Figure 5.3. Tumor multiplicity data for groups sampled for tumors macroscopically at eight months. *  
And + represent statistically significant difference (p<0.05) from the corresponding  
control group.  132 
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CHAPTER 6  
ENHANCEMENT OF DIETHYLNITROSAMINE  (DEN)-INDUCED  
HEPATOCARCINOGENESIS BY SHORT-TERM LACTATIONAL  
EXPOSURE TO INDOLE-3-CARBINOL (I3C)  
IN THE C57BL/6J MOUSE.  
A. Oganesian, J.M. Spitsbergen, and D.E. Williams.  
Toxicology Program, Marine/Freshwater Biomedical Sciences  
Center, Department of Food Science and Technology, Oregon  
State University, Corvallis OR.  139 
ABSTRACT 
I3C, a plant secondary metabolite found in cruciferous  
vegetables, inhibits various types of cancer in different  
animal models, including mammary tumors in rodents and is  
currently being evaluated in human clinical trials. However,  
depending on timing of administration, I3C is also capable  
of acting as a promoter of hepatocarcinogenesis in trout and  
rats. In this study, lactating female mice were given 0 or  
2000 ppm I3C in AIN76A diet, starting on day 8 after birth  
of litters and until weaning on day 21. Pups from all  
litters were injected ip with 5 mg/kg DEN on day 15. After  
weaning, pups were fed control diet, sacrificed at 8 months  
of age and examined for liver tumors. Mice from litters of  
dams fed I3C had a significantly higher tumor incidence  
(14/17 versus 4/11 for controls, p<0.001). In a short-term  
study involving lactating females fed rodent chow, AIN76A or  
2000 ppm I3C diet for one week, total P450 levels were  
significantly elevated in pup livers from both I3C and chow  
diet groups. EROD activity was induced 3-fold in the pups  
from I3C litters. We also observed radioactivity in the  
liver extracts of pups from PHII3C-gavaged dams, indicating  
transfer of I3C (or metabolites) through lactation. HPLC  
analysis of liver extracts showed a peak in all litters,  
corresponding in retention time to the linear trimer of I3C.  140 
We suggest that enhancement of DEN-initiated  
hepatocarcinogenesis in pups pre- and co-exposed to I3C  
condensation product(s) through lactation could be due to  
induction of various phase I enzymes which could be  
responsible for procarcinogen activation in this model.  141 
INTRODUCTION 
Indole-3-carbinol,  (I3C) a breakdown product of  
glucobrassicin from cruciferous vegetables has been shown to  
elicit & number of biological responses upon dietary  
administration, including chemoprevention of cancers in  
various animal models (1-9) in several target tissues. It is  
currently being evaluated as a possible chemopreventive agent  
for use against certain hormone-dependent cancers in humans  
(10). Mechanisms for inhibition of tumorigenesis by I3C  
include the alteration of estrogen metabolism (11-16),  
inhibition of glutathione-S-transferase-mediated steroid  
binding activity (17), and to a lesser extent, scavenging of  
free radicals (18), reversal of multidrug resistance (19), and  
alteration of the expression of various phase I and phase II  
drug-metabolizing enzymes (20-24) contributing to  
detoxification of carcinogenic compounds. Acid condensation  
derivatives of I3C are formed in the stomach upon dietary  
administration and are believed to be responsible for its  
biological effects (25-28). Some of I3C derivatives exhibit  
relatively high affinity for binding to the Ah receptor (29,  
30) as well as antiestrogenic and weak estrogenic activities  
(25). One of the major condensation products, the dimer  
3,3'diindolylmethane (133') is capable of inducing apoptosis  142 
in human cancer cells (32) and inhibits cytochromes P450  
activitiy in vitro (30, 33).  
Chemopreventive properties of I3C are usually reported  
when it is administered concurrently with the carcinogen or  
prior to the initiation. However, it was observed that, when  
given after initiation (promotion-progression stage), I3C can  
enhance tumorigenesis (1,  3, 7). There is also evidence that  
I3C may be mutagenic when administered in diet along with  
nitrites (34).  
In an earlier study, we reported that long term post- 
initiation dietary I3C protected against DEN-initiated hepatic  
tumors in the male C57BL/6J infant mouse model (6), supporting  
the hypothesis that long term I3C may have estrogenic effects  
in vivo. Estrogens are reported to have liver tumor promoting  
activities in rats (35, 36) and trout (37). However, mice are  
apparently not susceptible to estrogen-mediated promotion of  
hepatic carcinogenesis (38), and in fact, estrogens are  
reported to inhibit chemically induced hepatic tumors in  
certain strains of mice, including C57BL/6J (38, 39). In this  
study we examined whether short term lactational I3C,  
administered prior to and shortly after initiation ,  could  
alter tumor outcome in the offspring. Specifically, protection  
was hypothesized since I3C is known to inhibit tumorigenesis  
when given prior to initiation and concurrently with the  
carcinogen (3). We report here the unexpected finding that  143 
short-term lactational I3C enhanced liver tumor incidence in  
C57BL/6J mice and provide evidence for induction of P-450s as  
a possible factor for enhanced procarcinogen activation in  
this model.  144 
MATERIALS AND METHODS 
Chemicals  
I3C was purchased from Aldrich Chemical (Milwaukee,  
WI).Diethylnitrosamine (DEN) and other chemicals were  
purchased from Sigma Chemical Co.  (St. Louis, MO) and supplies  
from Fisher Scientific (Santa Clara, CA), unless otherwise  
noted. I3C was tritium-labeled at the 5 position using the  
method of Dashwood et al (40).  [3H]I3C was diluted with  
unlabeled I3C to an approximate specific activity of 0.1585  
Ci/mmol. The radiochemical purity of this compound was shown  
to be at least 95 % based on HPLC analysis using a Packard  
Radiomatic radioisotope detector.  
Animals  
All experimental procedures were conducted under NIH  
guidelines for the care and use of laboratory animals.  
c57BL/6J mice were purchased from Jackson Laboratory (Bar  
Harbor, ME) as litters, each containing 5 male pups.  
Animal Treatments, Diets, and Husbandry  
Starting from day 7, lactating female dams were fed  
powdered AIN76A semipurified rat/mouse diet,  (American  
Institute of Nutrition, prepared using components from ICN,  
Costa Mesa, CA) with no antioxidants, and containing 0 or 2000  145 
ppm I3C. I3C was added into the diet in dry powdered form.  
Once in mixtures, I3C is known to undergo spontaneous  
breakdown. For this reason the stability of I3C in the AIN76A  
powdered diet was monitored by HPLC (UV-detector). After 7  
days at least 80 % of I3C was still in the parent form. I3C  
diet was prepared once a week and stored at 4°C until used. On  
day 15, pups were injected ip with 5 mg/kg DEN in saline. DEN  
stock concentration was prepared such that for each g of body  
weight, mice received 10 gl stock solution. No liver tumors  
were seen in control (saline-injected) mice in previous tumor  
studies of the same duration, and it was decided not to  
include vehicle-injected control animals in this experiment.  
The average body weight at day 15 was around 6 g. Small gauge  
insulin syringes were used for injection procedures. Nine days  
after injection, pups were weaned and thereafter fed AIN76A  
control diet until termination of the experiment.  
Animals were housed at the Oregon State University  
Laboratory Animal Resources Center in plastic cages with  
polyurethane covers at one per cage, diet given daily, and  
water and bedding changed twice a week. Diet and water were  
available ad libitum. Mice were maintained under controlled  
conditions of temperature (21 ± 1°C) and humidity (50 ± 10%)  
and a light/dark cycle of 12 h. Clinical observations and  
body weights for individual mice were recorded weekly.  146 
The design for the short-term experiment following the  
tumor study was identical, except one more group of lactating  
mice, fed regular rodent chow diet instead of AIN76A, was  
added, and on day 15 (initiation day for the tumor study),  
dams and pups were sacrificed and the livers instant-frozen  
for further analysis. Four lactating dams fed I3C diet were  
twice given 100 4Ci [3H]I3C by gavage (dissolved in DMSO, corn  
oil suspension) 8 and 4 hours prior to sampling.  
Necropsy  
At eight months, mice were euthanized in a CO2  
chamber according to the 1993 AVMA panel on Euthanasia (41).  
Livers were examined grossly with a stereomicroscope during  
necropsy and numbers of neoplasms and pale foci recorded.  
Livers were fixed in 10% neutral buffered formalin,  
dehydrated in graded ethanols and embedded in paraffin. Four  
micrometer sections of liver were stained with H&E. At least  
3 pieces of liver,  1 piece taken from each of the 3 main  
lobes (median, L later and R lateral) of liver, were  
embedded and sectioned. If gross lesions were evident in the  
liver, additional pieces of liver containing lesions were  
embedded. Three sections of each piece of liver embedded  
were examined. Histologic findings in liver were interpreted  
according to criteria for rodent liver established by the  
International Agency for Research on Cancer (42) and the  147 
Society of Toxicologic Pathologists together with the  
American Registry of Pathology of the Armed Forces Institute  
of Pathology (43).  
Preparation of hepatic microsomes and enzyme assays  
Livers were homogenized in 4-5 volumes of ice cold 0.1 M  
potassium phosphate buffer (pH 7.4) containing 0.15 M KC1,  
mM EDTA and 1 mM phenylmethylsulfonyl fluoride (PMSF)  
(homogenization buffer). Microsomes were prepared by  
differential centrifugation according to Guengerich (44). The  
supernatant from a 10,000 g centrifugation of liver homogenate  
was subjected to centrifugation at 100,000 g. The resulting  
pellet was washed with potassium pyrophosphate buffer (0.1 M,  
pH 7.4,  1 mM EDTA, 1 mM PMSF), centrifuged at 100,000 g, and  
the pellet resuspended in homogenization buffer containing 20  
% glycerol to obtain microsomes.  
Protein determinations were made according to the method  
of Lowry et a/.(45).  
CYP1A1 activity was analyzed by the 7-ethoxyresorufin-O-
deethylase (EROD) assay, modified from Pohl and Fouts (46)  
using liver microsomes at 30° C.  
The  total  specific  content  of  cytochrome  P-450  was  
measured  spectrophotometrically  by  the  reduced-CO  versus  
oxidized-CO difference spectrum (44).  
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Recovery of radioactivity in liver and HPLC analysis  
Recovery of radiolabel was determined after 2 gavage  
treatments of 100 gCi CHiI3C 8 and 4 hours prior to sampling.  
Liver tissues were homogenized in homogenization buffer, 50 ml  
aliquots digested in BTS-450 tissue solubilizer (Beckman)  
according to manufacturer's instructions and color reduced  
with 200 gl of 30% hydrogen peroxide. All samples were stored 
in the dark overnight prior to quantifying radioactivity using 
a Beckman LS6500 liquid scintillation counter. 
A  Beckman ODS 5g 4.6 X 250 mm  HPLC reverse phase column 
was used to analyze for radioactive I3C and/or derivatives in 
liver extracts from dams and pups. Starting conditions were 
20% acetonitrile (Solvent A) and 80% Milli-Q water (MQ-1120, 
Millipore Corp., Bedford, MA) (Solvent B)  (31). These 
conditions were held for 30 sec, before changing to 15%  
solvent B over the next 29.5 min (linear gradient). This ratio  
was held for 5 min, then programmed to 0% MQ-H20 over the  
following 5 min, and returned to starting conditions over the  
next 10 min. The flow rate was 1 ml/min. Metabolites were  
monitored by radioactivity using a Packard Radiomatic  
radioisotope detector and liquid flow cell (scintillation  
cocktail flow rate was 3 ml/min). Liver homogenates (1-2 ml)  
were extracted three times in three volumes ice cold ethyl  
acetate containing 0.001% BHT. Liver extracts were evaporated  
under a gentle flow of nitrogen gas. The yellow-green residue  149 
was centrifuged at 14,000 g for 30 sec and 50-100 µl injected  
into the Beckman ODS 54 4.6 X 250 mm analytical column and  
detected as described above.  
Statistics  
Data for treatment groups of interest were compared by  
an unpaired, two-tailed t-test for tumor multiplicity data,  
and Fisher's two-tailed exact test for incidence data. All  
differences in observations with probability value of 0.05 or  
less were considered statistically significant.  150 
RESULTS 
Tumor incidence and multiplicity data are presented in  
Table 6-I. Tumor incidence was significantly higher in mice  
exposed to I3C through lactation (p < 0.001). Multiplicity  
data could not be interpreted clearly since one mouse from  
the control group exhibited 13 neoplasms, whereas the  
remaining three mice from the same group had only 1 tumor  
each. Data on foci of hepatocellular alterations are  
presented in Table 6-II.  
Total P-450 levels, measured in the pup livers from the  
short-term experiment, are presented in Fig. 6.1. Hepatic  
microsomal P-450 levels were significantly higher in pups  
from maternal I3C-exposed litters, as well as litters from  
the group where dams were fed chow diet. EROD activity,  
representing CYP1A1, was induced 3-fold in microsomes from  
pups exposed via lactation to I3C (data not shown).  
Radioactivity recovery in dam and pup livers was  
calculated as a percentage of DPMs (disintegrations per  
minute) of the original  radioactivity (3H) dose received  
(200 gCi). The recovery at this single time point was  
1.56±0.32 % of total dose received in livers from dams and  
0.0091±0.0012 % in livers from pups.  
Fig. 6.2 is a representative (one litter) HPLC  
chromatogram of detected radioactivity in dam and pups liver  151 
extract. A peak at around 29-30 min was observed  
consistently in all four litters from dams receiving  
(3I-11I3C. This peak is tentatively identified as the linear  
trimer (LT) of I3C which eludes under this conditions at  
about 29 min. Confirmation of the identity of this peak  
awaits further analysis.  152 
DISCUSSION  
The objective of this study was to test whether short  
term pre- and co-initiation exposure to I3C through  
lactational transfer protects against hepatocarcinogenesis in  
the offspring. We have reported that long-term dietary I3C  
inhibits hepatocarcinogenesis in the C57BL/6J infant mouse- 
initiation model. It is generally concluded that, when given  
prior to initiation and/or concurrently with the carcinogen,  
I3C elicits protection against chemically-induced  
carcinogenesis. One of the mechanisms of tumor inhibition  
relates to the induction of phase I and II isozymes  
responsible for shifting the carcinogen metabolism towards  
detoxification. This same mechanism, however, could be  
responsible for enhancement of initiation if particular P-450  
isozymes, responsible for procarcinogen activation (i.e.  
CYP1A1 and CYP1A2) are induced.  
Another candidate mechanism of action by I3C for  
modulating carcinogenesis involves estrogenic and/or  
antiestrogenic effects of dietary I3C. Estrogens inhibit  
chemical carcinogenesis in the mouse liver model (38). Our  
previous finding of inhibition of DEN-induced  
hepatocarcinogenesis by long term dietary I3C (6) supports the  
possibility of estrogenic effects of I3C, especially since in  
a similar experimental design, I3C promotes in trout and the  153 
rat liver. It is well established that the rat and trout are  
susceptible to promotion of liver tumors by estrogens (35-37).  
Furthermore, dietary I3C has been demonstrated to be  
estrogenic in trout as evidenced by enhanced levels of serum  
vitellogenin, an estrogen-dependent protein.  
In this study, infant mice exposed to I3C through  
lactational transfer for one week prior to initiation with a  
single 5 mg/kg ip injection of DEN and sampled for hepatic  
tumors at eight months, exhibited significantly enhanced liver  
tumor incidence compared to initiated mice from litters with  
dams fed control AIN76A diet. This is one of the first reports  
that pretreatment with dietary I3C results in enhancement  
rather than inhibition of chemically-induced carcinogenesis.  
Earlier studies report enhancement of tumor outcome only in  
experimental designs when animals were exposed to dietary I3C  
in a post-initiation long-term exposure time frame.  
Our finding that short-term lactational I3C pre-
treatment followed by co-treatment with the carcinogen  
enhances DEN-initiated hepatocarcinogenesis in the neonatal  
mice supports the speculation that I3C and/or its acid  
condensation derivatives may mediate chemically induced  
carcinogenesis by altering (inducing) P-450s responsible for  
procarcinogen activation. A future study with the congenic  
strain of C57BL/6J mouse, possessing a defective aryl  
hydrocarbon (Ah) receptor gene (C57BL/6J(Ahd/d)), could  154 
address the question of whether or not the mechanism of  
enhancement in this model is linked to Ah receptor-mediated P-
450 induction.  
We conclude that the proposed dietary supplementation  
of I3C in humans for chemoprevention purposes should be  
approached with caution, until its mechanism(s) of  
carcinogenesis modulation in different animal models and  
their relation to human cancer risk are thoroughly  
understood.  155 
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work was supported by US PHS grant ES 04766.  Table 6 -I. Histologic hepatic neoplasia in mice receiving lactational  
exposure to 13C prior to initiation with DEN  
Treatment  Total Hepatic  Hepatocellular  Hepatocellular  Neoplasm 
Group  Neoplasia (%)  Adenoma (%)  Carcinoma (%)  Multiplicitya 
(n litters)  
Control(3)  4/11(36)  2/11(18)  3/11(27)  1(1-13)  
I3C(4)  14/17b(82)  11/17(65)  13/17(76)  6(1-11)  
a  
median number of neoplasms detected histologically in liver  of  
mice bearing neoplasia (range).  
significantly different from control (p < 0.001)  Table 6-11. Foci of hepatocellular alteration in mouse livers  
Treatment  Total Foci  Amphophilic  Eosinophilic  Basophilic  
Group  (%)  Foci (%)  Foci (%)  Foci (%)  
(n litter)  
Control(3)  10/11(91)  10/11(91)  2/11(18)  0/11(0)  
I3C(4)  16/17(94)  16/17(94)  3/17(18)  4/17(24)  
b  Average number of foci of cellular alteration detected histologically in  
liver of mice with foci (range).  
Focus  
Multiplicityb  
3(1-10)  
3(1-6)  0.50 
Total P-450 Levels: Short-Term Mouse Study 
"53 0.40 
2 0 
0) 0.30 
* 
0 
E 0.20 
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0.00 
control  chow diet 
* indicates significant difference from control 
13C 
Figure 6.1. Induction of total microsomal P-450 levels in pups exposed to I3C through  
lactation for seven days. Total P-450 levels were higher in pups from dams fed  
chow and I3C diet. * Represent statistically significant difference (p<0.05)  
from the control diet (AIN76A) group.  600 
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Figure 6.2. A representative HPLC chromatogram of detected radioactivity in dam and pups liver  
extract. A peak at around 29-30 min was observed consistently in all four litters  
from dams receiving  We propose that this peak corresponds to the linear  
trimer (LT) of I3C which normally eludes at about 29 min.  160 
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Chapter 7  
SUMARY  
Modulation of chemical hepatocarcinogenesis by dietary  
I3C is linked to several mechanisms. The relevance and/or  
relative importance of a particular mechanism depends upon  
the animal species, target organ, and conditions of the  
experiment, especially the dose and timing of  
administration. The fact that most biological responses  
observed after dietary I3C exposure are postulated to be  
dependent upon one, some or perhaps all of the 15-20 various  
acid condensation derivatives, complicates the matter even  
further, since the yield of various derivatives could be  
expected to vary greatly between species and depending on  
conditions of dietary administration.  
Two of the most important mechanisms for tumor  
modulation by I3C and/or its acid derivatives are (in no  
particular order):  (i) Ah receptor-mediated enzyme induction  
and (ii) estrogenic and/or antiestrogenic response(s).  
In the 9,000 trout tumor study involving a wide range  
of the initiator dose (AFB,), significant promotion of  
hepatocarcinogenesis was apparent at dietary levels of I3C  
as low as 500 ppm (also at 250 ppm, but only at the higher  167 
end of the AFB1 dose range). The pattern for potency of  
promotion by I3C suggests a possible role of more than one  
mechanism involved. Estrogenicity of dietary I3C, measured  
as its ability to dnduce plasma vitellogenin, an estrogen  
biomarker protein, was detected at the lowest treatment  
levels and increased in a dose-dependent fashion. In  
contrast, CYP1A levels in trout livers from the same study  
were induced at just the highest dietary levels (1000 and  
1250 ppm), suggesting that Ah receptor pathway while active,  
is perhaps relevant for explaining the observed promotion at  
only relatively high dietary levels of I3C.  
In the C57BL/6J infant mouse model, long-term dietary  
I3C inhibited DEN-induced tumor multiplicity, consistent  
with a hypothesis supporting an estrogenic mechanism(s) of  
I3C action, as it is known that estrogens inhibit  
chemically-induced liver tumors in mice. However, in another  
tumor study involving the same mouse model, designed to test  
the ability of short-term pre- and co-treatment with dietary  
(lactational) I3C to protect against hepatocarcinogenesis,  
resulted in significant enhancement of tumor incidence  
compared to initiated control animals. In a follow-up  
experiment, it was seen that P-450 levels in pup livers were  
markedly induced following one week of lactational I3C  
exposure, suggesting that induction of xenobiotic  
metabolizing enzymes responsible for procarcinogen  168 
activation could be an important deciding factor in the  
tumor outcome, especially for a sensitive model such as the  
infant mouse. Interestingly, the nursing pup seemed to  
accumulate I3C condensation products selectively, with the  
linear trimer apparently absorbed to a much greater extent  
in the infant liver than other I3C products and/or is  
excreted/eliminated at a slower rate compared to other  
derivatives.  
Future studies are recommended with I3C addressing the  
relative role(s) that particular I3C acid condensation  
derivatives could have in modulating chemical  
carcinogenesis, particularly, 133', which is the major  
condensation product of I3C, and the linear trimer which may  
be selectively accumulated in infant liver through  
lactation.  
The relevance of results obtained from different animal  
models to human cancer risk will depend on understanding the  
factors behind observed species differences in response to  
dietary I3C. For example, if estrogenic effects of long-term  
dietary I3C can be documented in humans, then concerns could  
be raised regarding risk(s) associated with possible  
increase in human liver cancer incidence, since it is known  
that estrogens promote hepatic adenomas and carcinomas in  
humans.  169 
In conclusion, there might be a real potential in using  
I3C for the purpose of cancer chemoprevention. However,  
before any large-scale supplementation is recommended for  
humans, a thorough understanding of its mechanisms of action  
as a carcinogenesis modulator is critical.  170 
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